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1.0  Introduction 
Hypertension or high blood pressure is a silent disease which can lead to many 
complications (e.g. cardiovascular diseases, stroke and kidney diseases) and death if it is 
not treated. Hypertension commonly refers to high blood pressure when the pressure of 
artery is too high. It is classified into two classes: essential hypertension and secondary 
hypertension. Essential hypertension is hypertension that is not caused by secondary 
conditions such as those that affect kidneys, arteries, heart or endocrine systems. On the 
other hand, secondary hypertension is hypertension that is caused by the secondary 
conditions. According to the National Health and Morbidity Survey II, the prevalence of 
this illness in Malaysia is 24% higher compared to cancer, cardiac related disease and 
diabetes mellitus. Based on Asia-Pacific Cohort Studies, Alexandra Martiniuk 
suggested that two out of three heart attacks and strokes occurred in Asia are caused by 
hypertension (Martiniuk et al., 2007). Furthermore, at least 970 million people 
worldwide have elevated blood pressure; with about 330 million in developed countries 
and around 640 million in developing countries. The World Health Organization rates 
this disease as one of the important cause of premature death worldwide and this 
problem keeps on increasing through time. It is estimated about 1.56 billion adults will 
live with high blood pressure in 2025 (Kearney et al., 2005). 
Due to the rapid increase in the number of people with hypertension at present 
and prospected in the future; several preventive strategies are being carried out 
worldwide to control this disease. Hypertension is a complex disease which could 
originate via a simple mechanism or a combination of various mechanisms. Due to this 
reason, anti-hypertensive drugs that have been commercialized are normally designed 
for a specific mechanism such as diuretic drug, beta-blocker drug, calcium channels 
drug, Angiotensin Converting Enzyme (ACE) inhibitors and many more.  Education in 
schools, rural places, hospitals and through multimedia is some of the ways taken by 
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certain countries to control this disease. Promotions on a healthy lifestyle help to control 
and prevent essential hypertension. Besides, intake of a balanced diet, supplements and 
herbs or natural products together with frequent exercise and a better lifestyle may help 
to reduce or control this disease.  
  Due to the emergence of several reported side-effects of synthetic drugs usage, 
patients start to seek for some alternative solutions to help them reduce or control their 
hypertension. In recent times, many researchers explore the advantages of using natural 
products for human consumptions and try to evaluate their effects on several diseases 
including diabetes mellitus, cancer as well as hypertension. Examples of natural 
products derived from foods, herbs and fruits that have been studied for the treatment of 
hypertension include onion, garlic, grape seed, hibiscus, European mistletoe (Viscum 
album), Indian snakeroot (Rauwolfia serpentina), olive leaf, reishi and other 
mushrooms, hawthorn leaf and flower extract, Coleus forkoshlii, ginsengs and many 
more. Apocynum venetum Luobuma leaves and Lepidium sativum L were reported to 
exhibit antihypertensive effects in Spontaneously Hypertensive Rats (SHR) upon daily 
administration (Kim et al., 2000; Maghrani et al., 2005).  Allium ursinum, Amelanchier 
ovalis, Cistus clusii and Lespedezae capitata showed active potential as  ACE inhibitor 
in an in vitro screening of ACE activity inhibition using HPLC (Wagner et al., 1991). 
Interestingly, flavanoids, procyanidins and peptides were isolated  in the study with anti 
– ACE potential (Elbl & Wagner, 1991; Wagner & Elbl, 1992). 
Thus far, none of the studies on natural product medicinal plants reported the 
effect of Ficus deltoidea Jack towards hypertension. F. deltoidea is a houseplant or a 
shrub that belongs to family of Moraceae (Brickell & Zuk, 1997). The synonym is Ficus 
diversifolia Blume (Barley & Barley, 1976). In Malaysia, this plant is widely known as 
Mas Cotek or Secotek Emas that is referring to the golden spots on the upper surface of 
its leaves. According to traditional practitioners, this plant has been used to treat various 
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health conditions for example as treatment after childbirth and birth control. It is also 
used to improve blood circulation, reduce blood cholesterol, control high blood pressure 
and others. However, these claims still lack of scientific evidence to support them. 
Other than these claims, several local researchers have discovered the potential of this 
plant in lowering blood glucose level (Adam et al., 2009; Aminudin et al., 2007), as an 
antinociceptive agent (Sulaiman et al., 2008), as anti-oxidant (Abdullah et al., 2009; 
Hakiman & Maziah, 2009) and as anti-ulcer agent (Siti-Fatimah-Zahra et al., 2009).  
This present study was conducted to evaluate the effect of F. deltoidea aqueous 
extracts in reducing hypertension. Experiments were conducted using SHR rats. Rat 
sera were collected and analyzed using proteomics techniques. A preliminary study on 
ACE inhibitory activity was done to determine the potential of this plant in having anti-
hypertensive property. Captopril (a synthetic ACE inhibitor) was used as the positive 
control.  
Proteomics is a large scale proteins study particularly on its structures and 
functions (Anderson & Anderson, 1998; Blackstock & Weir, 1999). In this study, SDS-
PAGE was used initially to monitor the changes in serum protein profile with reference 
to their molecular weights. Proteins that were altered (in terms of their expressions) 
following the treatment with F. deltoidea extracts were further separated using two-
dimensional gel electrophoresis (2-DE) analysis. 2-DE separates serum proteins based 
on its isoelectric point (pI) and molecular weight (MW) (Klose, 1975; O'Farrell, 1975). 
Image Master Platinum 7.0 Software (GE Healthcare Biosciences), a bioinformatics 
tool was used to analyse the protein spots on 2-DE gels. This determined significant 
changes in expression of the serum protein(s). Proteins that exerted significant changes 
in their expression were identified using Matrix Assisted Laser Desorption / Ionisation –
Time of Flight/ Time of Flight (MALDI-TOF/TOF), a high throughput mass 
spectrometry technology. 
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The complexity of serum protein with the presence of highly abundant proteins 
such as serum albumin and immunoglobin renders difficulties in detecting the 
differentially expressed protein of low abundance as well as those with low MW 
(Merrell et al., 2004). Thus, to monitor the low MW serum protein that maybe affected 
by F. deltoidea extracts, Surface Enhanced Laser Desorption / Ionisation- Time of 
Flight (SELDI-TOF) was used to complement the investigation (Hutchens & Yip, 1993; 
Papale et al., 2008).  
The use of proteomics tools in this study will help to achieve the aim of 
identifying the protein(s) expression affected by the administration of F. deltoidea 
extracts in vivo. This in turn will give further insight(s) of the possible mechanism(s) 
involved. 
                                                                                                            
 
 
 
                            
 
 
 
 
 
 
  
C
h
ap
te
r 
1
: I
n
tr
o
d
u
ct
io
n
  
5 
 
 
The objectives of this study are; 
 To investigate the effects of F. deltoidea towards Angiotensin Converting 
Enzyme activity. 
 To monitor the alterations of serum proteins expression in SHR rats following 
administration with F. deltoidea extracts. 
 To identify serum proteins that may potentially involved in hypertension.  
 To monitor the effects of F. deltoidea aqueous extracts on SHR rats’ serum low 
molecular weight proteins expression. 
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2.0  Literature Review 
2.1  Ficus deltoidea  
Ficus deltoidea is a small plant derived from Moraceae family locally known as 
Mas Cotek among the Malays especially in Kelantan. This plant also known as Secotek 
Emas, Telinga Beruk, Telinga Gajah, Serapat Angin and other names based on its 
varieties. Detailed morphological studies to differentiate the varieties have not yet been 
reported. The name Mas Cotek refers to the presence of golden spots on the upper leaf 
surface. In the Malay language, golden spots can be directly translated as Mas or Emas 
(gold) and cotek (spot). 
F. deltoidea can be classified into „male‟ and „female‟ varieties. However, this 
classification is not associated with the plants‟ gender but rather a classification based 
on morphological characteristics. The male variety has smaller leaves (SL) with red 
spots on the underside whereas the leaves of the female variety are bigger in size and 
have black spots. The female variety can be further divided based on the size of the 
leaves; plant with medium type leaves (ML) and large type leaves (BL). Fruits borne by 
the male variety are smaller (SF) compared to female (Figure 2.1). F. deltoidea can 
easily grow as epiphytes and can abundantly be found on the beaches of Kelantan and 
Terengganu. However, due to public awareness towards the extinction of natural 
product resources recently, this plant is now grown in many plantations in Malaysia. 
These plantations cater to the increasing demand by the consumer due to its reported 
benefits. F. deltoidea has been claimed to provide many health benefits. This could be 
due to the presence of phytochemicals such as phenols, proanthocyannins, triterpenoids, 
tannins and flavanoids.  
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Figure 2.1: The characteristics of F. deltoidea.  
(A) F. deltoidea plant from the big leaf variety depicting fruits and leaves. Golden 
spots can be seen on the upper surface of the leaves.  
(B) F. deltoidea plant from small leaf variety showing the leaf and fruit. Note the 
red spot on the underside of the leaf.  
 
A 
B 
Red spot on the 
underside of the leaf 
Small fruit 
Big fruit 
Golden spot on the 
surface of the leaf 
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2.1.1  Benefits of F. deltoidea 
Traditionally, several types of herbal plants found in Malaysia have been used as 
remedy to treat various ailments. Examples include Gynura procumbens (Akar Sebiak) 
as an anti-hypertensive agent, Pereskia sacharosa (Pokok Jarum Tujuh Bilah) as an 
anti-cancer agent, Eurycoma longifolia (Tongkat Ali) as an aphrodisiac for men and 
Labisia pumila (Kacip Fatimah) for general health in women. According to traditional 
practices, F. deltoidea has been used as a decoction or tea to treat fever, increase and 
recover sexual desire, reduce cholesterol, remove toxins and improve blood circulation. 
Interestingly, F. deltoidea can be used by both sexes unlike E. longifolia which is used 
by men to increase virility or L. pumila which is used by women to facilitate childbirth. 
 Research on the benefits of this plant is generating great interest among 
scientists. This is in part due to positive results demonstrated by the consumers in the 
traditional use of this plant. Hakiman and Mahmood (2009) reported that the aqueous 
extract of F. deltoidea possesses positive non-enzymatic and enzymatic antioxidant 
activities based on 2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging 
assay, ferric reducing power assay, peroxidase activity, ascorbate oxidase activity and 
catalase activity. Sulaiman et. al. (2008) reported that F. deltoidea aqueous extract 
showed positive antinociceptive activity. Aminudin et. al. (2007) reported that both 
leaves and fruits extracts of F. deltoidea significantly reduced the external glucose load 
at a dosage of 50 mg/kg body weight in rats. According to Adam et. al. (2007), 1000 
mg/kg of F. deltoidea aqueous extract exhibited hypoglycaemic activity in post-prandial 
mild diabetic rats. F. deltoidea aqueous extract have been shown to exhibit positive 
effects towards uterine contraction which could be a possible explanation for the 
utilization of this extract during post-partum or after childbirth (unpublished data).  
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There is a concern among consumers regarding the toxicity of herbal plants. 
Therefore, researches have been performed to investigate the toxicity effects of these 
plants. Fazliana et. al. (2008) demonstrated that F. deltoidea var. Augustifolia aqueous 
extract showed no toxic effect on bone marrow, liver and renal functions following its 
administration to rats at 100 and 300 mg/kg body weight daily for 90 days. 
Our previous study showed that different varieties and plant parts of F. deltoidea 
produced good inhibitory response towards Angiotensin Converting Enzyme (ACE) 
(unpublished data). The study showed that the aqueous extracts of the fruit (from the 
small variety plant) and the leaves (from the big variety plant) of F. deltoidea could be 
potential candidates as anti-hypertensive agents.  
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2.2  Hypertension 
 Hypertension can be defined as sustained elevation of blood pressure in arteries 
that may cause organ damage and other adverse consequences. When blood pressure in 
arteries is increased, this will caused the heart to pump blood at higher pressure and 
forcing the blood to push against the vessels‟ wall.  Such conditions may cause organ 
damage (heart or kidney failure) and diseases such as cardiovascular disease (CVD) 
(Carretero & Oparil, 2000).  Organ damage is more severe with the development of high 
systolic blood pressure (SBP) compared to high diastolic blood pressure (DBP) (Cutler, 
1996). Individuals with higher blood pressure have a greater tendency to develop heart 
attack, stroke and kidney disease. The relationship between CVD and blood pressure is 
continuous, consistent and independent (Chobanian et al., 2003). 
 Hypertension is commonly divided into two groups; essential (primary) and 
secondary hypertension. Primary, essential or idiopathic hypertension is defined as 
hypertension with no identifiable cause. Secondary hypertension is hypertension caused 
by other medical problem such as kidney failure, hormones, diseases and tumour. 
Hypertension caused by the side effect from certain medication is also considered as 
secondary hypertension. About 90-95% of patients with high blood pressure belongs to 
the essential hypertension group (Carretero & Oparil, 2000). However, this theory is 
only partially accepted as little information is available on the genetic variation and 
intermediary phenotypes that may cause high blood pressure (Luft, 1998).  
There are several environmental factors which could increase blood pressure that 
include obesity, insulin resistance, high alcohol intake, high salt intake (in salt-sensitive 
patients), ageing and possibly a sedentary lifestyle, stress, low potassium intake and low 
calcium intake (INTERSALT-Co-operative-research-group, 1988; Sever & Poulter, 
1989). Based on these studies, ageing could also increase the risk of hypertension. Half 
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of individuals aged from 60 to 69 years old may develop hypertension whilst the 
majority of individuals with aged above 70 years old have higher probability to develop 
hypertension.  
However, the interaction between environmental and genetic factors influence 
the intermediary phenotypes and hence, may contribute to higher blood pressure 
(Carretero & Oparil, 2000). Therefore, people with essential hypertension have high risk 
to develop hypertension-related diseases if not treated. Changes in lifestyle, including 
reducing body weight, fat and alcohol intake, increasing potassium and calcium intake 
(Appel et al., 1997) together with exercise may reduce or normalize blood pressure in 
patients (Krotkiewski et al., 1979; Petrella, 1998).  
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2.2.1 Classification of hypertension 
  In the 7
th
 Report of the Joint National Committee (JNC 7) on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (2003) hypertension in 
adults aged 18 and above can be classified as shown in Table 2.1. 
 
Table 2.1: Classification of hypertension in adults reported in JNC 7.  
 
BP classification SBP mm Hg DBP mm Hg 
Normal < 120 and < 80 
Pre-hypertension 120-139 or 80-89 
Stage 1 hypertension 140-159 or 90-99 
Stage 2 hypertension ≥ 160 or ≥ 100 
 
Source: 7
th
 Report of the Joint National Committee (JNC 7) as reported by The National 
High Blood Pressure Education Program. 
 
 
Pre-hypertension is not considered as disease but it is a term referring to 
individuals with high risk of developing hypertension. Thus, both patient and clinicians 
will be alerted and encouraged preventive measures to be undertaken. This might help 
to avoid or delay the disease from developing. Individuals with pre-hypertension are not 
suitable candidates for drug therapy but are advised to practise lifestyle modification 
(Chobanian, et al., 2003). However, for those with diabetes and kidney disease, they 
need to be put on an appropriate drug therapy if the lifestyle modification fails to reduce 
their BP to 130/80mmHg or less. As for the individuals with hypertension (stage 1 and 
2), the treatment goal is to lower their BP to less than 140/90 mmHg. 
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2.2.2 Diagnosis of Hypertension 
2.2.2.1 Blood pressure (BP) Measurement 
 Clinically, patients were diagnosed based on the systolic and diastolic blood 
pressure levels using a device called sphygmomanometer. Systolic blood pressure 
(SBP) reading is the maximum pressure of blood when the heart contracts. Diastolic 
blood pressure (DBP) on the other hand is the minimum pressure in artery when heart 
relaxes. Generally, the normal blood pressure is 120/80 mmHg by where 120 is the 
systolic and 80 is the diastolic. Any measurement between 120/80 mmHg to 139/89 
mmHg is considered pre-hypertension. In this stage, a person has the potential to 
develop hypertension if BP is not controlled. Nevertheless, significant blood pressure 
measurement of more than 140/90 mmHg is considered hypertension (Table 2.1). 
In hypertension, monitoring of SBP is more important compared to DBP since 
clinical trials have demonstrated that controlled SBP reduces total mortality, 
cardiovascular mortality, stroke and heart failure in older people ( Staessen et al., 1999; 
Kostis et al., 1997). 
 
2.2.2.2 Cortisol level 
 Monitoring of the cortisol level in serum or urine has been suggested to be 
useful in the screening of the potential to develop hypertension and CVD in 
normotensive person.  Cortisol is usually released in the body due to fasting, food 
intake, exercising, awakening and physiological stressors (Wallerius et al., 
2003;Vicennati, 2002;  Ely, 1995; McEwen, 1980).  
Cortisol is a stress hormone by which its level in the body increases in response 
to stress. During normal stress response, the pituitary gland increases its release 
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of adrenocorticotropic hormone (ACTH). This hormone will then trigger the synthesis 
of cortisol from adrenal gland (adrenal cortex) to regulate blood pressure. Thus, in 
continuous stress, the cortisol will be synthesized higher than usual. This is normally 
observed once a person awake (Filipovsky, 1996) or when an individual is experiencing 
physical and emotional stress.  
Study suggested that excess of cortisol is associated with the increase of BP and 
altered the intermediary metabolism, which results in obesity, insulin resistance and 
abnormal lipid metabolism (Connell et al., 1986). They have also reported that free 
cortisol excretion rates in urine are higher in hypertensive subject. Therefore, it is 
important to monitor the level of cortisol for patients with high cortisol level but normal 
BP as a precaution step to prevent or delay the occurrence of hypertension and / or 
CVD.  
The following list represents the normal range cortisol level in blood and urine. 
Blood 
 adults (8 am)    : 6-28 mg/dL  
 adults (4 pm)      : 2-12 mg/dL 
 child one to six years (8 am)  : 3-21 mg/dL 
 child one to six years (4 pm)   : 3-10 mg/dL 
 newborn     : 1-24 mg/dL. 
Urine 
 adult    : 10-100 mg/24 hours 
 adolescent    : 5-55 mg/24 hours 
 Child    : 2-27 mg/24 hours. 
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2.2.3 Medication to treat hypertension 
 There are several types of medication available to lower high blood pressure and 
it may be necessary to take more than one type of medication to control the blood 
pressure effectively. However, the combination depends on the physiological condition 
of the patient. For this reason, it is important for the patient to take the medication 
properly as directed. Otherwise, the medicine may not work, or it could also cause side 
effects.  Degree of the side effects varies, ranging from mild to severe. 
Drugs used as high blood pressure medication can be divided into eight common groups 
which include: 
 Diuretic  
 Beta blockers 
 ACE (Angiotensin Converting Enzyme) inhibitors 
 Angiotensin II receptor blockers 
 Calcium channel blockers 
 Alpha blockers 
 Vasodilators 
 Central Acting Adregenic Agents  / Central Alpha Agonists 
 
Among those listed, diuretics, beta blockers and ACE inhibitors are the 
commonly used drugs in treating patients with hypertension. 
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2.2.3.1 Diuretic medications for hypertension 
 Diuretics are drugs known as „water pills‟ due to its effects in assisting the 
flushing out of excess water and sodium in the body through urination. In addition to 
high blood pressure, diuretics are often used to treat other illnesses including abnormal 
heart function, oedema and sometimes poisoning. The target organs of this drug are 
kidneys. Different diuretics work on different part of the kidney. There are three classes 
of diuretics used to treat hypertension: (1) thiazides, (2) loop-active agents and (3) 
potassium-sparing agents. These agents act as either mineralcorticoid antagonists or 
inhibitors of the epithelial sodium channel located at late distal renal tubule or collecting 
duct. 
 Thiazide diuretics such as hydrocholorothiazide and benzoflumethiazide could 
be used as monotheraphy or in combination with β-blockers, ACE inhibitors or 
angiotensin receptor blockers (Krakoff, 2005) . However, there are still arguments 
regarding the use of thiazide-type diuretics as the initial treatment for all hypertensive. 
Study from the Systolic Hypertension in the Elderly Program (SHEP) provided 
evidence that emphasizes a low-dose thiazide-type drug as initial therapy for isolated 
systolic hypertension in older patients (Kostis et al., 2005). Moreover, the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) strongly supports the use of this drug as the best choice for African-
American hypertension (Wright et al., 2005).  
 Loop-active agents, furosemide and its analogs (bumetanide or torsemide) 
interrupt re-absorption of sodium, calcium and potassium in the distal renal tubule at the 
ascending limb of the Loop of Henle at sites distinct from the thiazide-sensitive loci. 
These loop-active agents have a short duration of action and for treatment of 
hypertension, must be given twice daily (Krakoff, 2005). 
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 Potassium-sparing diuretics are mineralcorticoid antagonists and sodium channel 
antagonists known as spironolactone, eplerenone, amiloride and triamterene. 
Spironolactone can be highly effective in many patients with refractory hypertension in 
combination with a thiazide-type diuretic and can correct hypokalemia as well. 
However, gynecomastia is a limiting adverse reaction for men treated with 
spironolactone because of the antiandrogenic effect of this drug. Premenopausal women 
treated with spironolactone may develop menstrual irregularities, so spironolactone is 
most likely to have sustained acceptance only by postmenopausal women. Eplerenone 
should be considered an alternative for those who have a good clinical response to 
spironolactone but develop unacceptable adverse reactions. Amiloride and triamterene 
are also customarily used drugs that inhibit the epithelial sodium transport channel of 
the collecting duct (Krakoff, 2005).  
 Usage of diuretics may provide side effects to the consumer. After prolonged 
use of diuretics, sudden withdrawal can reduce body‟s potassium level which leads to 
weakness, fatigue and leg cramps. The less common side effect that affect long term 
diuretics intake is gout. Besides, some of these hypertension drugs can increase blood 
glucose levels. 
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2.2.3.2 Beta blockers medication for hypertension 
 Beta blockers are drugs used to block the effects of the sympathetic nervous 
system on the heart. It will reduce body‟s requirement for blood and oxygen and thus 
reducing the workload of the heart. As a result, the heart doesn‟t have to work as hard, 
which in turn lowers BP. They help to control heart beat rate and are also used in the 
treatment of abnormal heart rhythms that may too fast or irregular. 
 Examples of beta blockers include:  
 acebutolol 
 betaxolol 
 bisoprolol 
 esmolol 
 propanolol 
 atenolol 
 labetalol 
 cardevilol 
 metoprolol 
 nevibolol 
There are three known types of beta receptors, designated as β1, β2 and β3. β1-
adrenergic receptors are located mainly in the heart and kidneys. β2- adrenergic 
receptors are located mainly in the lungs, gastrointestinal tract, liver, uterus, vascular 
smooth muscle and skeletal muscle while β3 receptors in fat cells. The use of β-blockers 
as first line therapy for hypertension has been widely conceptual for a long time and 
many debates have continued ever since. 
Wink (2001) stated that a combination of β-blockers and diuretics is more 
efficient in preventing morbidity and mortality in elderly patients with hypertension. 
Kahn and McAlister (2006) concluded that in trials comparing other antihypertensive 
medication with β-blockers, all agents showed similar efficiency in younger patients, 
while in older patients; β-blockers were associated with a higher risk of both composite 
events and strokes. Therefore, patients over 60 years old with ischemic heart disease or 
heart failure should still be prescribed β-blockers for heart failure and angina. Also, in 
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older patients with hypertension who need multiple agents to control their blood 
pressure, a β-blocker could be added as a third or fourth agent in addition to a diuretic, 
ACE inhibitor, Angiotensin II receptor blocker or calcium-channel blocker. Metoprolol 
is a good choice, even though it is expensive but it has been proven to reduce mortality 
in patients with a history of myocardial infarction or heart failure.  
The side effects of β-blocker consumption include insomnia, tiredness, extreme 
cold, depression and symptoms of asthma. Moreover, consumption of β-blocker drugs 
in a diabetic person undergoing insulin treatment should be monitored. 
  
2.3.3.3 Angiotensin Converting Enzyme (ACE) Inhibitors for hypertension 
 ACE inhibitors trigger the production of vasodilators by inhibiting the formation 
of angiotensin II. This vasoconstrictor is formed by the proteolytic action of renin 
(released by the kidneys) acting on circulating angiotensinogen to form angiotensin I. 
Angiotensin I is then converted to angiotensin II by ACE. This system is called the 
renin-angiotensin system (Figure 2.2). 
 ACE also breaks down bradykinin (a vasodilator substance). Therefore, ACE 
inhibitors, by blocking the breakdown of bradykinin help to increase bradykinin levels. 
The increased bradikinin level can contribute to Nitric Oxide (NO) activation resulting 
in the relaxation of vascular smooth muscle (vasodilation) thus lowering BP. Increase in 
bradykinin is also believed to be responsible for a troublesome side effect of ACE 
inhibitors, namely, dry cough. 
 Angiotensin II constricts arteries and veins by binding to Angiotensin II receptor 
type 1 (AT1) located on the smooth muscle, which are coupled to a Gq-protein and the 
inositol trisphosphate (IP3) signal transduction pathway. Angiotensin II also facilitates 
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the release of norepinephrine from sympathetic adrenergic nerves and inhibits 
norepinephrine reuptake by these nerves. This effect of angiotensin II augments 
sympathetic activity on the heart and blood vessels. 
 The first ACE inhibitor marketed, captopril, is still in widespread use today. 
Although newer ACE inhibitors differ from captopril in terms of pharmacokinetics and 
metabolism, all the ACE inhibitors have similar overall effects on blocking the 
formation of angiotensin II. ACE inhibitors include benazepril, enalapril, fosinopril, 
moexipril, quinapril and ramipril. 
 ACE inhibitors actions normally will dilate the arteries and veins by blocking 
angiotensin II formation and inhibiting bradykinin metabolism. This vasodilation 
reduces arterial pressure, preload and afterload on the heart. Furthermore, it down 
regulates sympathetic adrenergic activity by blocking the facilitating effects of 
angiotensin II on sympathetic nerve release and reuptake of norepinephrine. ACE 
inhibitors also promote renal excretion of sodium and water (natriuretic and diuretic 
effects) by blocking the effects of angiotensin II in the kidney and also by blocking 
angiotensin II stimulation of aldosterone secretion. This reduces blood volume, venous 
pressure and arterial pressure. It also inhibits cardiac and vascular remodelling 
associated with chronic hypertension, heart failure and myocardial infarction.  
 Elevated plasma renin is not required for the actions of ACE inhibitors, although 
ACE inhibitors are more efficacious when circulating levels of renin are elevated. 
Renin-angiotensin system is distributed in many tissues, including heart, brain, vascular 
and renal tissues. Therefore, ACE inhibitors may act at these sites in addition to 
blocking the conversion of angiotensin in the circulating plasma. Cough and angiodema 
is the side effect of ACE inhibitor. If administered in the second or third trimester of 
pregnancy, ACE inhibitors can cause a number of fetal anomalies including 
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aligohydramnios, fetal calvarial hypoplasia, fetal pulmonary hypoplasia, fetal growth 
retardation, fetal death, neonatal anuria and neonatal death (DiBianco, 1986; Pryde et 
al., 1993). For this reason, ACE inhibitors should be used with caution in women of 
child-bearing potential. 
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Figure 2.2: Renin-angiotensin system. This system involves various organs such as liver, pulmonary and kidneys in its circulation. ACE is 
released by pulmonary and kidneys as Angiotensin I produced from the synthesis of Angiotensinogen in the liver. The proteolysis of 
Angiotensinogen to Angiotensin I are activated by renin released by the kidneys.  
Angiotensinogen Angiotensin I Angiotensin II 
Renin 
ACE 
ACE INHIBITOR 
LIVER 
KIDNEYS 
LUNG 
KIDNEYS 
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2.3.3.4 Other anti-hypertensive drugs.  
Table 2.2: Other types of anti-hypertensive drugs. 
Type  Mechanism of action & Side effect(s) Drugs Name 
Angiotensin II receptor blockers Mechanism 
Protect blood vessels from the angiotensin II hormone. 
Instead of lowering hormone levels, these drugs keep 
the hormone from interacting with blood vessels. As a 
result, the vessels become more dilated and blood 
pressure goes down. 
Side effect 
Occasional dizziness. 
losartan, candesartan, irbesartan, 
eprosartan,  
valsartan, telmisartan 
Calcium channel blockers (calcium 
antagonist) 
Mechanism 
This type of anti-hypertensive drug keeps calcium from 
moving into the muscle cells and causing constriction 
of blood vessels. As a result, blood vessels relax and 
blood pressure is lower. 
Side effect(s) 
Swollen ankles, heart palpitations, constipation, or 
dizziness.  
Nifedipine, bepridil, verapamil, 
diltiazem, amlodipine, nimodipine, 
felodipin, nisoldipine 
 C
h
ap
te
r 
2
: L
it
er
at
u
re
 R
ev
ie
w
 
24 
 
 
Table 2.2 (continued): Other types of anti-hypertensive drugs.  
Alpha blockers Mechanism 
Alpha blockers reduce another sympathetic nerve 
impulse to blood vessels, which permits easier 
passage for blood, thus reducing pressure. 
Side effect(s) 
Quicker heart rate, dizziness, and a sudden drop in 
blood pressure when standing. 
Doxazosin mesylate,  
Prazosin hydrochloride,  
Prazosin and polythiazide, 
Terazosin hydrochloride, 
 
Vasodilators Mechanism 
Vasodilators are an older class of drugs that work to 
open blood vessels by relaxing vessel walls, resulting 
in lower blood pressure. 
Side effect(s) 
Headaches, heart palpitations, swelling around the 
eyes, as well as achy joints.  
Loniten (minoxidil) can cause excess hair growth and 
weight gain. 
 
Hydralazine hydrochloride, Minoxidil 
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Table 2.2 (continued): Other types of anti-hypertensive drugs 
 
Central Acting Adrenergic Agents  
/ Central Alpha Agonists 
Mechanism 
Prevents the brain from sending signals to the heart and blood 
vessels, which slows the heart and prevents blood vessels from 
constricting. 
 
Side effect(s) 
Sudden drop in blood pressure especially when the patient 
stands or walks, which can lead to weakness or fainting. Other 
possible side effects are drowsiness, dry mouth, fever, 
constipation, and anaemia. Men might experience impotence. 
 
clonidine hydrochloride, 
 methyldopa and 
hydrochlorothiazide, 
guanabenz acetate, methyldopa, 
clonidine hydrochloride and 
chlorthalidone, methyldopa and 
chlorothiazide, guanfacine 
hydrochloride 
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A number of hypertension medications have been commercialised and 
prescribed to patients. However, most of the patients do not succeed in keeping their 
blood pressure under control. This is because the medications were prescribed with 
wrong combinations. Physicians often choose the drugs by trial and error and monitor 
which combination work best.  
 Three guidelines for drug prescription in hypertensive patients have been 
proposed. Firstly, it has been suggested that the effects of prescribed drugs are different 
in different ethnic groups (Gupta et al., 2010). Patient‟s age and race can also be used as 
a guideline for second line treatments. Other studies involved renin levels. Turner and 
his group (2010) found that the level of renin can be an effective method for selecting 
blood pressure medication. They also stated that patients with higher renin levels should 
not be prescribed with a diuretic because they responded better to beta-blockers. 
Alderman (2010) suggested that patients with low renin levels should be prescribed 
with diuretic drugs rather than anti-renin agents and vice versa.  
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2.2.4 Natural product medication 
 Due to the side effects of synthetic drug usage, many researches on foods, 
animals and plants are attempting to identify compounds that can be utilized in 
controlling hypertension. A common herb which is usually used in daily cooking that is 
known to have anti-hypertensive effect is garlic (Allium sativum). 
It has been shown that garlic has the potential to treat mild or moderate 
hypertension at a dosage of 600-900 mg garlic powder per day for twelve weeks (Silagy 
& Neil, 1994a). This study was conducted on 415 patients and it was found that there 
was a typical drop of 7.7 mmHg systolic and 5 mmHg diastolic BP. However, higher 
doses of garlic may be more effective as McMahon and Vargas (1993) demonstrated 
that a dosage of 2400 mg caused a drop of 16 mmHg drop in DBP after only five hours 
of administration. Besides its effects on BP, garlic also have positive effect in the 
lowering of cholesterol level  and prevention of atherosclerosis (Silagy & Neil, 1994b).  
 An example of natural product from animal origin that has potential to treat 
blood pressure is Sea Cucumber or known as gamat in Malaysia.  Sea Cucumber is 
usually used by the Chinese to nourish blood, moisturize dryness-syndrome, regulate 
menstruation, help in recovery after child delivery, as well as a tonic for the kidney. It is 
also used in treating ulcers, dysentery, impotence, arthritis pain, weakness and recovery 
from illness. It also helps to regulate blood lipid and blood pressure, promote blood 
circulation as this animal has been claimed to contain Omega 3 and 6. However, no 
scientific experimental data is available.  
 The International Collaborative Study of Macronutrients and Blood Pressure 
(INTERMAP) reported that addition of vegetables in daily diets also helps in 
significantly reducing BP. In the report, they found that high BP of patients with higher 
consumption of vegetable amino acid together with animal amino acids (cysteine, 
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proline, phenylalanine and serine) has lower BP compared to others. This could be due 
to the presence of glutamic acid in vegetables.  
 Recently, many scientific studies on the effect of natural products have been 
done worldwide. The effect of natural products as an anti-hypertensive is commonly 
screened using preliminary in vitro ACE inhibitory activity assay. An example of 
natural product that has been evaluated using this assay is a tuber storage protein from 
yam (Dioscorea alata cv. Tainong No. 1) known as dioscorin. The IC50 of dioscorin 
using FAPGG as substrate was 6.404 µM dioscorin. (Hsu et al., 2002). The ethyl acetate 
extract of Rabdosia coetsa, a medicinal plant from China also showed ACE inhibitory 
activity. Three isolated compounds from the extract, ethyl caffeate, rosmarinic acid and 
methyl rosmarinate exhibited 32.42%, 55.19% and 39.50% ACE inhibition respectively 
at the concentration of 10 µg/ml using HHL as the substrate (Li et al., 2008).  
Other plants  that have potential to inhibit ACE are Brazillian Strawberry (Pinto 
et al., 2008),  rapeseed (Pedroche et al., 2004),  Undaria pinnatifida or known as 
wakame or seaweed (Suetsuna et al., 2004), milled whole grain (Nogata et al., 2009) 
and green tea (Persson et al., 2010) and many more.  
 Study on hypertension using SHR is widely used to monitor the anti-
hypertensive effect in vivo.  SBP observation of SHR supplemented with ethanol 
extracts of pink guava (Psidium guajava) within four weeks exhibited reduction of BP 
(Ayub et al., 2010). Cinnamon extract also helps in reducing blood pressure in SHR 
which received diet containing starch and sucrose (Preuss et al., 2006). In China, Xin 
Jiang red raspberry fruit ethyl acetate extract showed dose-dependent antihypertensive 
effect through nitric oxide activation and improved vascular endothelial dysfunction (Jia 
et al., 2011).  
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2.3 Proteomics 
 Proteomics is a large-scale in vivo protein study which involves a variety of 
high-throughput techniques and new technology. The term was first coined by Peter 
James in 1997 (James, 1997). Proteomics is a study of the proteome. The word 
proteome was first introduced by Wilkins (Wasinger et al., 1995) where the word 
proteome comes from proteins (prot) and genome (ome). Wilkins described proteome 
study as a study of the entire complement of proteins expressed by the genome, cells, 
tissue or organism. However, a study of the proteome is more complex than the 
genome. This is because it involves knowledge of protein structure and functional 
interaction between proteins instead of only looking at the sequences. The study of the 
proteome also includes the understanding of how the proteins are involved in pathways.  
Anderson and Anderson (1998) stated in their article that the aim of proteomics 
is to explain “a comprehensive, quantitative description of protein expression and its 
changes under the influence of biological perturbations such as disease or drug 
treatment.” Normally, the objectives of proteomics research are to discover the protein 
expressions, quantification, protein identification and proteins with related-function in a 
proteome (Abdullah-Soheimi et al., 2010; Amacher et al., 2005; Piubelli et al., 2005).  
A standard gel-based proteomics research workflow involves; (1) separating the 
proteins through two dimensional gel electrophoresis (2-DE), (2) visualisation using 
Coommasie blue staining or silver staining, (3) quantification of the protein spots using 
gel image analysis and (4) identification of the proteins using mass spectrometry (MS). 
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2.3.1 Sodium dodecyl sulphate polyacrilamide gel electrophoresis  
 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) is a 
protein fractionation technique first introduced by Laemmli (1970) using Tris-base 
buffer. Laemmli developed this technique by combining two established methods; 
development of PAGE (Davis, 1964; Ornstein, 1964) and the importance of SDS 
addition to PAGE (Shapiro et al., 1967). SDS, a dissociating agent will denature the 
native proteins to individual polypeptides.  Approximately 1.4g of SDS will wrap 
around 1 g of polypeptides backbone and once this mixture was heated at 100°C it will 
produce negatively charge polypeptides. The negatively charged polypeptides will move 
towards the anode in electrophoresis through the SDS polyacrylamide gel with the aid 
of tris-base buffer (PAGE). Beta-mercaptoethanol and dithiothreitol (DTT) were used as 
dissociating agents to disrupt disulphide bonds of native proteins. This technique have 
been popularly cited by many researcher as it can be used to determine the MW of 
separated proteins based on its relative mobility (Weber & Osborn, 1969).  SDS-PAGE 
has been used in proteomics as the preliminary study to examine the range of protein 
MW and to determine the presence of interfering substances such as salt in extracts or 
sample before proceeding to isoelectric focusing (IEF) system (Cilia et al., 2009).  
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2.3.2 Two dimensional gel electrophoresis (2-DE) 
 Two-dimensional gel electrophoresis (2-DE) was first introduced in 1975 by 
Patrick H O-Farrell (1975) and J. Klose (1975). It is a proteomics tool that is capable of 
resolving up to thousands of proteins in one biological sample. The term „two 
dimension‟ comes from the separation of proteins on the basis of its isoelectric point 
(pI) by isoelectric focusing (IEF) and its MW by SDS-PAGE. Originally, the first 
dimension was performed in carrier ampholyte-containing polyacrylamide gels cast in 
narrow tubes. However, in the late 1980s, A. Görg and colleagues established a new 
technique in IEF whereby they introduced immobilised pH gradients (IPG) strips (Görg 
et al., 2000; Görg et al., 1987; Görg et al., 1978). 
 In IEF, the protein sample was first solubilised and disaggregated in rehydration 
buffer containing urea or thiourea, zwitterionic detergent such as CHAPS, carrier such 
as IPG buffer, denaturing agent; DTT and a tracking dye. Prior to IEF, to avoid 
aggregation and intermolecular interaction protein samples must be ensured to be fully 
denatured and soluble. Urea acts as a denaturant to solubilise and unfold the proteins, 
and hence expose the ionisable group to the solution. Zwitterionic agent, CHAPS, is 
more effective compared to other agents (NP-40 or Triton X-100). It has similar 
function to urea but it prevents aggregation through hydrophobic interactions. Carrier 
ampholytes such as IPG buffer is used to increase the solubility of protein by reducing 
aggregation via charge to charge interactions. DTT, a denaturing agent, allows cleaving 
of the disulphide bond and maintains the reduced state of proteins. Reduced protein 
samples will be loaded onto IPG gel strips either by using in-gel or cup-loading 
methods.  
 In IEF or first dimension step, proteins are separated based on its pI either to the 
positive or negative ends of the IPG strips. Proteins with a positive net charge will move 
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towards the cathode until it reaches its pI. Negatively charged proteins will move 
towards the anode until it reaches its pI. This is the focusing part where all proteins are 
separated on the basis of its pIs and this allows separation of proteins even when the 
difference of charge is small. The focusing requires high voltage for better resolution.  
Following the 1
st
 dimension, the strips will be equilibrated. This step ensures all 
proteins are saturated with SDS for SDS-PAGE separation. SDS buffer containing Tris-
base, urea, glycerol, reductant, SDS, and dye will maintain the solubility of the protein 
and improve protein transfer into the second dimension gel. Replacement of 
iodoacetamide with reductant in additional equilibration buffer prevents streaking and 
artifacts during electrophoresis. The concept of electrophoresis in second-dimension 
follows the principle of SDS-PAGE with the exception of a stacking gel. Equilibrated 
IPG strips on the second-dimension gel will be sealed with agarose to prevent the strip 
from floating during electrophoresis. This allows the focused proteins to penetrate into 
the second dimension gel.  
Thousands of proteins will be separated in the second dimension gel. Staining 
procedure is required for visualisation of proteins. Depending to the ease of use, 
sensitivity and compatibility to mass spectrometry (MS), different procedures can be 
utilized.  
Coomassie Brilliant Blue (CBB) is a common and traditional visualization 
technique. It was first introduced by Volker Neuhoff in 1985. The dye was named after 
an African City, Kumasi. This procedure has become a favourite in SDS-PAGE protein 
visualization due to the ease of use and its compatibility with MS analysis. There are 
two types of CBB; R-250 and G-250. The latter is less sensitive compared to the former. 
CBB binds to proteins through ionic interactions between sulfonic acid groups and 
positive protein amine groups through Van der Waals interaction. However, this 
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procedure has limited sensitivity where the minimum detection limit is in the range of 
200 – 500 ng proteins (Wilson, 1979). However, there are several reasons why this 
method is still widely used; (1) Low cost- where only a few chemicals are required 
compared to other staining procedures. (2) CBB staining is visible with eyes when the 
entire protein-dye complexes are formed. (3) No specific scanner is required. (4) Allows 
quantitative analysis. (5) Easy handling and less time consumption. (6) Compatible with 
MS analysis without any modification in the staining procedure (Westermeier, 2006).  
Silver staining is often preferred due to its high sensitivity (minimum detection 
limit of up to 1 ng protein)  (Ocbs et al., 1981; Shevchenko et al., 1996). Originally, this 
procedure is not compatible with MS analysis due to the incorporation of aldehyde. 
Aldehyde groups modify the lysine residue which forms complex with silver which is 
the fundamental principle of this procedure. The modification that promotes silver-
protein complex formation reduces the digestion of peptides by proteolytic enzyme and 
thus reduces the efficiency of peptide extraction. In order to overcome this problem, 
Shevchenko et al. (1996) suggested replacing aldehyde with sodium thiosulfate.  
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2.3.3 Protein identification by Matrix Assisted Laser Desorption/Ionisation - 
Time of Flight/ Time of Flight (MALDI-TOF/TOF) 
 
 Matrix Assisted Laser Desorption/Ionization (MALDI), a laser based soft 
ionisation technique introduced in 1988. It is a powerful technique used to examine 
large ionic molecules such as peptides and proteins through mass spectrometry ( Tanaka 
et al., 1988; Karas et al., 1987).  Time of Flight (TOF) mass spectrometry is commonly 
coupled with MALDI as the analyser to analyse ions. However, for better resolution and 
sensitivity in proteomics study, a next generation tandem mass spectrometry (MS/MS) 
technique has been developed for MALDI where the element of TOF/TOF is 
introduced. In TOF/TOF, two modes of MS operation are utilised. In the first MS mode, 
the sample is hit by a laser beam. Matrix will facilitate and accelerate vaporisation and 
ionization of the sample. Common matrices such as 3,5-dimethoxy-4-
hydroxycinnamic acid (sinapinic acid), α-cyano-4-hydroxycinnamic acid (alpha-cyano 
or alpha-matrix) and 2,5-dihydroxybenzoic acid (DHB) will co-crystallize with the 
protein sample and protect the sample from the laser beam. The resulting ions will be 
analyzed based on its mass to charge ratio, m/z. In the second MS mode, collision-
induced dissociation (CID) is introduced where some of the ionised molecules is broken 
into smaller fragments and detected by the mass spectrometer. 
 MALDI-TOF/TOF is a proteomics technique used in identification of proteins 
called mass fingerprint or peptide mass mapping (Medzihradszky et al., 2000). MALDI 
mass fingerprint typically performed on 2-DE gel spots (e.g. 2DE-coomasie blue, 2DE-
silver staining, 2DE-DIGE and etc). Due to complexity of some biological sample with 
numerous proteins, separation of proteins to individual spots is required (Blackstock & 
Weir, 1999). This is then followed by the excision of protein spot of interest from the 
gel.  The particular protein spots were then cleaved into smaller piece of peptides using 
a proteolytic enzyme, trypsin (Quadroni & James, 1999). Peptides were then extracted 
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from the gel and contaminants were removed using chromatographic column such as C-
18. This cleaning-up procedure helps to improve the spectra in mass spectrometry 
(Yates, 2000). The protein identification using mass spectrometry is achieved by 
comparing the mass of the protein sample with the mass fingerprint of peptides derived 
from the databases (MASCOT from Matrix-Science or ProFound from Proteometrics).  
 
 
2.3.4 Surface-Enhanced Laser Desorption/Ionization-Time of Flight  
(SELDI-TOF) 
 
 Surface-Enhanced Laser Desorption/Ionization (SELDI) original concept was 
first described by Hutchens and Yip (1992). SELDI-TOF is a high-throughput technique 
particularly used to investigate low molecular weight proteins (<20 kDa) up to 
femtomole sensitivity (Papale et al., 2008). This technique is one of the easiest 
techniques to handle due to its ability to examine native proteins with less laborious 
sample preparation required. Only a small quantity of sample (about 1-10 µg protein per 
spot) is required in running SELDI-TOF compared to 2-DE. Besides that, SELDI-TOF 
provides a better resolution for proteins with extreme low MW, hydrophobicity and pI 
which is often limited in other proteomics technique such as 2-DE (Seibert et al., 2004). 
The principle of SELDI-TOF that combines chromatography with mass 
spectrometry allows unwanted proteins to be separated from the sample mixture. This is 
the easier way to identify biomarker in complex biological specimen which depends on 
the targeted characteristics of the proteins. This technique allows the discovery of 
several biomarkers from biological sample and this will facilitate diagnosis of diseases 
(Li et al., 2002; Jr et al., 1999).  
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SELDI-TOF is a fully automated machine completes with robotic handling 
system such as Auto-Loader-equipped ProteinChip Reader, barcode-labelled arrays and 
ChiphergenExpress™ Data Manager Software. Therefore, multiple samples (up to 100) 
can be prepared and analysed in a short period. Results will be presented as spectra 
which exhibited signal intensity in correlation with protein concentration. Analysis of 
spectra using Expression Difference Mapping application can be directly performed 
once data has been obtained from the ProteinChip Reader. This machine also provides 
another software - Biomarker Pattern Software - to observe the expression of proteins 
and protein profiles. These informations can be used for biomarker discovery (Seibert, 
et al., 2004).  
The components of SELDI-TOF are (1) protein chip arrays (2)  mass analyser 
and (3) data analysis software (Issaq et al., 2003). Protein chip arrays are the important 
components that differentiate SELDI-TOF from other MS. Two types of 
chromatography are available i.e. chemical surface (hydrophobic, hydrophilic, ionic 
and immobilized metal affinity capture [IMAC]) and biochemical surface (antibody, 
DNA, enzyme, receptor and drug) (Figure 2.3). The common surfaces include CM10, 
H50, IMAC30 and Q10. CM10 is a protein array coated with weak anionic carboxylate 
group which functions as a weak cation exchanger. This array captures positively 
charged analytes such as lysine, arginine and histidine. Q10 functions in an opposite 
manner to CM10. It captures molecules with positive charge such as aspartate and 
glutamate due to the presence of cationic groups (quaternary ammonium group) on the 
array. In order to separate large proteins/peptides, H50 can be used. It allows the 
separation of proteins based on hydrophobicity. IMAC30 is used to analyse metal-
binding proteins, phosphorylated proteins and polyhistidine-tagged proteins.  This array 
is coated with the nitrilotriacetic acid (NTA) group which will chelates metal ions in the 
presence of histidine, tryptophan and cysteine. These components provide different 
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chemistry surfaces designated to retain proteins with specific characteristics. The entire 
bound proteins/peptides will then mix and crystallize with matrix such as alpha-cyano-
4-hydroxycinnamic acid (CHCA) or sinapinic acid (SPA) to facilitate ionization of the 
sample. 
 
 
 
                         
Figure 2.3: Protein arrays surfaces. Figure was extracted from Ciphergen. 
 
 
The second component in SELDI-TOF, the mass analyser, shares the same 
principal with other mass spectrometry. In this step, the retained proteins on the protein 
array will be deionised or ionised by irradiation with a nitrogen laser. All the ionised 
proteins/peptides will then pass through a flight tube and detector. Results are expressed 
as mass to charge ratio (m/z) values and intensities of the proteins/peptides. The 
detector also presents the protein profile of the specific biological sample.  
The third component, the analysis software - EDM - helps in detection of unique 
proteins upon comparison between multiple protein profiles. It also provides 
quantitative analysis by comparing different intensities of the same protein mass. 
Significance of differences in protein expression is determined during this analysis.  
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3.0 Methodology 
3.1 List of chemicals  
Angiotensin Converting Enzyme (ACE) activity inhibitory assay 
Angiotensin Converting Enzyme (Sigma: A 6778 -1UN; EC: 3.4.15.1), N-
Hippuryl-His-Leu hydrate (Sigma: H1635-500mg), sodium hydroxide, boric acid, 
sodium chloride (Merck), dioxane, cyanuric chloride, hydrochloric acid, KH2PO4 and 
hippuric acid. 
 
Animal studies 
 Diethyl ether, Captopril (Sigma) 
 
SDS-PAGE 
Acrylamide, N,N’- methylenebisacrylamide, Sodium dodecyl sulphate (SDS), 
Tris-Base, hydrochloric acid, ammonium persulfate (APS),  N, N, N’, N’ – 
tetramethylethylenediamine (TEMED),  Sodium hydroxide (NaOH), Bromophenol 
blue, Tris HCL, glycerol, β-mercaptoethanol (Merck), broad range prestained protein 
marker (Bio-Rad Laboratories Inc.), acetic acid glacial, methanol, Commasie Briliant 
Blue R250. * 
 
Protein Content Estimation 
Pierce BCA Protein Kit (Thermo Scientific) 
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Two Dimensional Electrophoresis (2-DE) 
 Urea, CHAPS, IPG buffer, bromophenol blue, DTT, Tris Base,Glycerol, SDS, 
Glycine, Acrylamide, Bis-acrylamide, APS, Agarose, n-butanol or t-butanol,  absolute 
ethanol, 25% glutaryldehyde, sodium thiosulphate, sodium acetate trihydrate, silver 
nitrate, formaldehyde, sodium carbonate, EDTA-Na2H2O, drystrip cover fluid and paper 
wicks (GE Healthcare). * 
 
MALDI-TOF/TOF 
Ammonium bicarbonate, potassium fericyanide, sodium thiosulphate, DTT, 
iodoacetamide, acetonitrile (ACN), ammonium bicarbonate, Trypsin Gold (PROMEGA, 
EC: 3.4.21.4), α-cyano-4-hydroxycinnamic acid (CHCA), triflouroacetic acid (TFA) 
and formic acid. * 
 
SELDI-TOF 
CM low-stringency buffer, pH 4.0 or sodium acetate buffer (Bio-Rad 
Laboratories Inc.) and matrix CHCA. * 
 
*All chemicals were purchased from SIGMA unless otherwise stated. 
*All solvents were purchased from SIGMA unless otherwise stated. Solvent for 
proteomics analysis were of HPLC grade. 
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3.2 Animal subjects  
Spontaneously Hypertensive Rats were purchased from Animal House, Faculty 
of Medicine, University of Malaya, Kuala Lumpur. 
 
3.3 Experimental plant materials  
Raw materials of F. deltoidea were purchased from Delto Medicama (M) Sdn 
Bhd. The plant samples was identified and stored in the Herbarium, Rimba Ilmu, 
University of Malaya with the voucher specimens numbers: KLU 046470 – Big type 
leaves, KLU 046467 – Small type fruit. 
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3.4 List of equipments and apparatus 
Heater (Thermolyne) 
Stirer (Thermolyne) 
Electronic Dry Cabinet (WEIFO®) 
Microplate reader (ASYS UMV 340) 
Centrifuge (Amersham Biosciences) 
Spectrophotometer (Model: Ultraspec 2100 Pro UV/Visible spectrophotometer) 
Dual vertical mini gel unit (Model: MGC-206, C.B.S Scientific Co.) 
Power supply (Model:PSU 400/200) 
Microcentrifuge (Model: Micro 20 Hettich Zentrifugen) 
Immobiline
TM
  Drystrip Reswelling Tray (GE Heathcare Biosciences) 
1D Ettan IPG phor 3 (GE Healthcare Biosciences) 
2D EttanDalt six gel caster (GE Healthcare Biosciences) 
2D EttanDalt six electrophoresis (GE Healthcare Biosciences) 
Image Scanner III (GE Healthcare Biosciences) 
Temperature controller (Model: 631-Protech) 
Electrophoresis Power Supply (Model: EPS 601) 
Speed Vacuum Concentrator (Thermoscientific) 
C 18-ZipTips (Eppendorf) 
Dual filter tips (100-1000 µl, 20-200 µl, 0.5-10 µl) (Eppendorf) 
MALDI plate (Applied Biosystems) 
MALDI-TOF/TOF mass spectrometer (Model: AB4800 plus, Applied Biosystems) 
ProteinChip CM-10 array (Bio-Rad Laboratories, Inc.) 
Bioprocessor reservoir (ProteinChip cassette and reservoir) (Bio-Rad Laboratories, Inc.) 
ProteinChip SELDI-TOF system (PSC 4000) (Bio-Rad Laboratories, Inc.)  
Pierce® BCA™ Protein Assay Kit (Thermo Scientific) 
 C
h
ap
te
r 
3
: M
et
h
o
d
o
lo
gy
 
42 
 
3.5 Preparation of F. deltoidea extracts 
3.5.1 Preparation of fruit aqueous extract (SF) 
Dried ground fruits of F. deltoidea, 100 g, was immersed in 500 ml of distilled 
water (ratio 1:5) and boiled for two hours. After two hours, another 500 ml of distilled 
water was added and boiling was continued for another two hours. The extract was 
filtered using sieve cloth once it was cooled to room temperature. The filtrate was then 
concentrated until it reaches at least 800 ml by heating at lower temperature (50-60⁰C). 
Centrifugation was performed at 4,500 x g, 10 minutes to remove sediments. Following 
that, the solution was poured into several freeze drying flask and stored in -80⁰C 
freezer. The frozen extract was then freeze-dried to yield fine dark brown powder. The 
plant extract was kept in capped container in WEIFO® Electronic Dry Cabinet with 
humidity below 30%. 
 
3.5.2 Preparation of leaves aqueous extracts (BL) 
 Dried ground fruits of F. deltoidea, 100 g, was immersed in 1000 ml of distilled 
water (ratio 1:10) and boiled for two hours. After two hours, another 1000 ml of 
distilled water was added and boiling was continued for another two hours. Subsequent 
extraction procedures were conducted as describe in Section 3.5.1. 
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3.6 Angiotensin Converting Enzyme (ACE) activity inhibitory assay 
ACE activity inhibitory assay by Paul L. Hurst and Chris J. Lovell-Smith (1981) 
was conducted in this study with some modifications. Synthetic substrate, Hippuryl-L-
histidine-L-leucine (HHL) was used to measure the ACE activity by which ACE will 
hydrolyzes this HHL to hippurate. Cyanuric chloride in 1, 4-dioxane was used as the 
reagent, where it reacted towards hippurate in the presence of phosphate buffer. 
 
 3.6.1 Preparation of reagents / solutions 
ACE, 0.04 U/ml 
 ACE from rabbit lung (SIGMA: A 6778-1UN) was dissolved in 5 ml of distilled 
water to reach a final concentration of 0.2 U/ml. This stock solution was kept in 
microcentrifuge tubes as aliquot and stored at -20°C until used. Prior to the experiment, 
300 µl of 0.2 U/ml of the aliquot was diluted five times with 1200 µl of distilled water. 
This enzyme solution was maintained in ice bath during the experiment. 
 
N-Hippuryl-His-Leu hydrate (HHL) substrate solution, 20 mM 
 The substrate N-Hyppuryl-His-Leu-hydrate, 500 mg, (SIGMA: H1635) was 
dissolved in 58.2 ml of 0.02 M NaOH. Substrate solution was kept at -20°C. In reagent 
blank tubes, the substrate solution was replaced with 0.02 M NaOH instead of 
incubation buffer. 
 
Note: NaOH was used to dissolve the HHL due to prevent appearance of precipitates that may affect the 
final concentration of substrate. 
 C
h
ap
te
r 
3
: M
et
h
o
d
o
lo
gy
 
44 
 
Hippurate standard solutions 
 Hippurate standard was prepared by diluting the stock solution (2500 µmol) into 
1250 µmol and 250 µmol with distilled water. All the three concentrations were used as 
standard in this experiment. The stock solution was kept in -20°C. 
 
Incubation buffer (Borate buffer) pH 8.3 
 Boric acid (H3BO3), 0.99 g, and NaCl, 9.35 g, were dissolved in 150 ml of 
distilled water. The pH was adjusted to 8.3 using 5 M NaOH and topped up to 200 ml 
with distilled water. Solution was stored at room temperature. 
 
Terminating solution, 1 M Hydrochloric Acid (HCl) 
 Hydrochloric acid, 1 M, was prepared by diluting 85.1 ml of 36% HCl and 
topped up to one litre with distilled water. Solution was stored at room temperature. 
 
Neutralizing solution, 1 M NaOH 
 NaOH, 40 g, was dissolved in one litre of distilled water. Solution was stored at 
room temperature. 
 
Diluent buffer or 0.2 M phosphate buffer pH 8.3 
 KH2PO4, 27.22 g, was dissolved in 900 ml of distilled water. The pH was 
adjusted to 8.3 using 5 M NaOH and topped up to one litre with distilled water. Solution 
was stored at room temperature. 
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Colouring reagent  
 Cyanuric chloride, 7.5 g, was dissolved in 250 ml of 1, 4-dioxane. Solution was 
stored at room temperature in a dark-brown glass bottle. 
 
0.02 M NaOH 
 NaOH, 0.16 g, was dissolved in 200 ml of distilled water. Solution was stored at 
room temperature. 
 
5 M NaOH 
 NaOH, 40 g, was dissolved in 200 ml of distilled water. Solution was stored at 
room temperature. 
 
3.6.2 Preparation of sample 
 Both extracts (fruits, SF and big leaves type, BL of F. deltoidea) were prepared 
by dissolving the extracts with distilled water until it reaches 4 mg/ml. Samples were 
then diluted ten times and serial dilution was done to reach final concentration between 
0 - 0.4mg/ml. 
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3.6.3 ACE Activity Inhibitory Assay 
 Three sets of centrifuge tubes were prepared in replicates. One set will be used 
for sample and another two sets were used for sample blank and hippurate standard. For 
sample and sample blank sets, 50 µl of sample (0.05, 0.1 and 0.2 mg/ml of SF and BL 
extracts), 100 µl of incubation buffer and 50 µl of 0.04 U/ml ACE solution were added 
together. However, for the control, 50 µl of distilled water was added to replace the 
sample. For the hippurate standard, 50 µl of hippurate standard solution (250 µmol, 
1250 µmol and 2500 µmol) and 150 µl of incubation buffer were added into the tubes. 
For the reagent blank (0 µmol of hippurate), 50 µl of distilled water and 150 µl of 0.02 
M NaOH were added into the tubes. All the tubes were vortex and pre-incubated at 
37°C for five minutes. At the same time, the ACE substrate solution was equilibrated 
for five minutes at 37°C. 50 µl of 0.02 M HHL and 0.02 M NaOH was then added into 
the sample set and the hippurate standard set respectively to start the reaction for 15 
minutes at 37°C. Then, 250 µl of terminating solution was added into all tubes to stop 
the reaction and 30 seconds later, the mixture was neutralized by the addition of 250 µl 
of 1 M NaOH. After the neutralization, 1 ml of diluent buffer was added to all tubes 
followed by 750 µl of colouring reagent. This mixture was vortex-mixed vigorously and 
allowed to stand for five minutes before it was vortex-mixed again. Then, all tubes were 
centrifuged at 3000 rpm for five minutes to remove all the denatured protein and excess 
cyanuric chloride. For sample blanks, terminating and neutralizing solutions were added 
before the addition of substrate. Absorbances of the supernatants were measured at 382 
nm using microplate reader versus the reagent blank. 
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3.7 Animal studies 
Eight weeks old male Spraque Dawly Rat (SD) and Spontaneously Hypertensive 
Rat (SHR) were purchased from the Animal House of Faculty of Medicine, University 
of Malaya, Kuala Lumpur. Animal study was conducted in the Experimental Block, 
Faculty of Medicine. Animal were caged individually, maintained on a 12 hour light, 12 
hour dark cycle at constant temperature and given gold coin palette and tap water ad 
libitium. Rats were divided into five groups with four rats in each group based on the 
type of treatment as shown in Table 3.1.  
 
Table 3.1: Rats grouping based on treatment received. 
Group Treatment 
Group 1 Normal rats or normotensive rat (NR) : SD : distilled water 
Group 2 Diseased: SHR rats : distilled water 
Group 3 Treated disease: SHR treated with fruit aqueous extract of F. deltoidea 
Group 4 Treated disease: SHR treated with big type leaf aqueous extract of  
F. deltoidea 
Group 5 Treated disease: SHR treated with captopril 
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3.7.1 Treatment with aqueous extracts 
For the treatment with aqueous extract solutions (group 3 and group 4), the 
dosage given to each rat was 75 mg/kg body weight. Based on the weight of SHR rat, 
(approximately 300 g), 22.5 mg of extract will be given to each rat. In this study, the 
plant extracts were given as drinking water to prevent experimental stress towards the 
SHR rats. The drinking water solution was prepared by dissolving 1.125 g of each 
extract in 2.5 litre of distilled water and was kept in 4°C. 30 ml of the extract solution 
were given daily for each individual rat, for ten days. 
 
3.7.2 Treatment with inhibitor, Captopril 
In this study, Captopril was used as the positive control. Dosage given to SHR 
rat (Group 5) was 60 mg/kg body weight. Each rat was treated with 0.125 mg of 
Captopril. One tablet of Captopril, approximately 25 mg, was dissolved in 100 ml of 
distilled water. For each rat, 30 ml of this solution was given daily for ten days.  
 
3.7.3  Serum extraction 
On the 11
th
 day, each one of the rat was brought to unconsciousness using 
diethyl ether saturated glass cage for a few seconds. Subsequently, the rat was laid 
down on the tray and blood was collected directly via cardiac puncture. The blood was 
then transferred into chilled micro centrifuge tube and spun for five minutes at 5,000 
rpm to obtain the serum. Serum was then transferred into another labelled tube and 
stored in -80°C freezer.  
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3.8 Estimation of serum protein content using BCA™ Protein Assay Kit 
 The protein content in each serum was estimated using Pierce BCA™ Protein 
Assay Kit. Two µl of serum was diluted 100 times and subjected to protein content 
estimation using test tube procedure. Bovine serum albumin (BSA) was used as the 
standard (5-250 μg/ml). All the experimental procedure was done according to the 
protocol as mentioned in the kit (Appendix D).  
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3.9 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis  
(SDS-PAGE) 
 
3.9.1  Preparation of reagents/solutions 
Solution A:  30% (w/v) Acrylamide and 0.8% (w/v) N, N’-methylenebisacrylamide 
Acrylamide, 60 g, and N, N’- methylenebisacrylamide, 1.6 g, were dissolved in 
200 ml of double distilled water. The solution was then deionised using Amberlite MB-
1. Deionised solution were stirred for one hour and later filtered. The filtrate was then 
stored in a dark bottle and kept at 4⁰C. 
 
Solution B: 1.5 M Tris-HCl pH 8.8  
Tris-Base, 36.35 g, was dissolved completely in 200 ml of double distilled 
water. The pH of the solution was then adjusted to 8.8 using concentrated hydrochloric 
acid (HCL). This solution was kept at 4⁰C. 
 
Solution C: 10% (w/v) SDS 
 SDS, 10 g, was dissolved completely in 100 ml of double distilled water and 
was kept at room temperature. 
 
Solution D: 10% (w/v) Ammonium persulfate (APS) 
APS, 0.1 g, was dissolved completely in one ml of double distilled water. The 
solution was freshly prepared before use or kept at -20⁰C. 
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Solution E: N, N, N’, N’ – tetramethylethylenediamine (TEMED) 
TEMED solution was taken directly from the bottle and kept in micro tube. 
 
Solution F: 0.5 M Tris-HCl , pH 6.8 
 Tris Base, 12.11 g, was dissolved in 200 ml of double-distilled water. The pH of 
this solution was adjusted to 6.8 using concentrated HCl. The solution was kept at 4⁰C. 
 
SDS-PAGE sample buffer: 1.0 % (w/v) Bromophenol blue, 62.5 mM Tris-HCl pH 
6.8 buffer (Solution F), 20% (w/v) glycerol, 10 % (w/v), β-mercaptoethanol 
Solution F, 2.0 ml, glycerol, 1.6 ml, 10% SDS, 3.2 ml, β-mercaptoethanol, 0.8 
ml and 1.0% bromophenol blue, 0.4 ml, were mixed together. The solution was kept in -
80°C. 
 
Cathode or trailing buffer: 2.5 mM Tris, 198 mM Glycine, 0.1% (w/v) SDS, pH 8.3 
Tris-Base, 3.30 g, glycine, 14.41 g, and SDS, 1.0 g, were mixed and made up to 
one liter with doubled-distilled water. pH was adjusted to 8.3 using concentrated HCL. 
 
Prestained Protein Marker (Molecular Weight: 6 – 175 kDa) 
The Prestained Broad Range Protein Marker (Bio-Rad Laboratories Inc.) was vortex 
well and aliquoted into separate tube. The marker was then heated to 95°C for five 
minutes. A quick 5 µl microcentrifuge spin was applied before loading it onto the gel. 
The remainder were kept in -20⁰C. 
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Coomassie Blue staining solutions 
Fixing solution: 10% acetic acid and 40 % methanol 
Acetic acid glacial, 10 ml, and concentrated methanol, 40 ml, were mixed and 
topped up to 100 ml of distilled water.  
 
Staining Solution: 0.1% Coomassie Brilliant Blue R- 250 in 10% of acetic acid. 
Coomassie Brilliant Blue R- 250, 1 g, and acetic acid, 100 ml, were mixed and 
dissolved in one litre of distilled water. The solution was then filtered and stored in dark 
bottle. 
 
Destaining solution:  10 % acetic acid 
Acetic acid glacial, 100 ml, was dissolved in distilled water to make up one litre 
and mixed thoroughly.   
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3.9.2 SDS-PAGE gel preparation 
Gel caster for Dual vertical mini-gel unit model # MGV-200 SDS-PAGE (C. B. 
S. Scientific CO.) was used to cast the SDS-PAGE gel with the thickness of 0.5 mm. 
 
3.9.2.1 Preparation of 12.5 % Separating Gel 
 Solution for separating gel was prepared by mixing all the solutions stated in 
Table 3.2. APS and TEMED were added last and the solution was stirred slowly for a 
few second to mix it well. Then the solution was immediately layered into the gel caster 
using a dropper. The gel was overlaid slowly with distilled water and allowed to 
polymerize for a minimum of one hour. 
 
3.9.2.2 Preparation of Stacking Gel 
 Stacking gel solution was prepared as shown in the Table 3.2 by finally adding 
APS and TEMED. Before preparing the stacking gel solution, the overlaid distilled 
water was removed and the surface of separating gel was dried using filter paper. 
Immediately, following the addition of TEMED and mixed properly, the stacking gel 
solution was layered onto the separating gel using a dropper and a comb was then 
inserted before the stacking gel starts to polymerize. 
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Table 3.2: Preparation of Separating Gel (12.5%) and Stacking Gel 
Solution  Separating Gel (12.5%) Stacking Gel 
Solution A 
8.34 ml 0.65 ml 
Solution B 5.00 ml - 
Solution C 0.20 ml 50.00 µl 
Double distilled water  6.36 ml 3.05 ml 
Solution F - 1.25 ml 
Solution D 100.00 µl 25.00 µl 
Solution E 6.60 µl 5.00 µl 
 
 
 
3.9.3 Preparation of serum sample for serum protein profile in SDS-PAGE 
All serum (normotensive rat, SHR treated with SF [SHR-SF] and BL extract 
[SHR-BL], SHR treated with Captopril [SHR-Cp] and nontreated SHR) collected from 
rats were used in the analysis. 5 µl of serums were mixed with 5 µl of sample buffer 
(ratio 1:1) in individual microcentrifuge tube. Then, 3.5 µl of the solution were heated 
about three minutes in boiling water and were loaded into different wells. Frozen 
Prestained protein standard marker was heated in 40°C about five minutes and 5-10 µl 
was loaded onto the gel. Separation of sample via SDS-PAGE was performed in 
triplicate. 
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3.9.4 Running SDS-PAGE 
The glass plates containing polymerised gels were assembled into the 
electrophoresis tank with the short plate facing on the inside. The comb was removed 
and electrophoresis buffer (cathode buffer) was poured between the gel cassettes until 
all wells were filled with the buffer. 
 3.5 µl of sample solution (refer method 3.9.3) was loaded using gel loading tip 
into respective wells. Lane 1 was loaded with normotensive rat serum; Lane 2 with SHR 
serum; Lane 3 and 4 with SHR-BL and SHR-SF serum and Lane 5 was loaded with 
SHR-Cp serum. Lastly, 10 µl of standard protein marker was loaded into the last well 
(lane 6).  
 The tank was then assembled appropriately and connected to the power supply 
correctly. The samples were allowed to run at 60 V for the first 15 minutes and 
eventually changed to 100 V when the dye reaches the separating gel. The voltage 
supply was terminated once the dye reaches 1 cm from the bottom of the gel.  
 
3.9.5 Staining and destaining procedure 
 Once the SDS-PAGE electrophoresis was completed, the gel was carefully taken 
out from the gel caster and immersed in fixing solution for 30 minutes with continuous 
shaking. Following the fixing solution was removed slowly by holding the end side of 
the gel. The fixing solution was then replaced with Coomassie Brilliant Blue R-250 and 
left with continuous shaking for 30 minutes. Then, the staining solution was replaced 
with de-staining solution and continuously shaked until the background of the gel was 
clear and the protein bands revealed. This de-staining procedure may took about 3 
hours. 
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3.9.6 Gel calibration and determination of unknown serum protein molecular 
weight (MW) 
 The molecular weight of proteins separateded in the gel was determined by 
comparing the distance travelled relative to the marker called relative mobility (Rm). 
The MW of the proteins was determined from the calibration curve of the protein 
standards’ MW versus its Rm (Table 3.3). Calibration curve was prepared by plotting the 
log 10 MW of the standards proteins versus relative mobility, Rm. The Rm was 
determined by the following formula: 
               Rm     =      Distance of protein migration 
                                               Distance of tracking dye migration  
 
   
Table 3.3: Molecular weight of protein standard. 
Protein Standard Molecular Weight (kDa) 
Myosin 210 
Β-galactosidase 125 
Bovine serum albumin 101 
Ovalbumin 55.2 
Carbonic anhydrase 35.8 
Soybean trypsin inhibitor 29 
Lysozyme 21 
Aprotinin 6.9 
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3.10 2-D Electrophoresis 
3.10.1 Preparation of reagents 
 
Urea rehydration stock solution 
 (8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.002% bromophenol blue) 
 
Urea, 12 g, CHAPS, 0.5 g, IPG buffer, 125 µl and 1% Bromophenol blue stock 
solution, 50 µl, were mixed and double-distilled water (ddH2O) was added up to 25 ml. 
This solution was stored in 1ml aliquots at -20⁰C.  
 
Urea rehydration buffer 
(8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.002% bromophenol blue, 0.0028% 
DTT) 
 
DTT, 0.1 g, was added into 1ml of urea rehydration stock to obtain 10% DTT in 
the solution. 28 µl of this solution was then added to the other 1ml urea rehydration 
stock solution prior to use. This urea rehydration buffer was used in sample rehydration 
(Section 3.10.2). 
 
 
 
 
 
 
 C
h
ap
te
r 
3
: M
et
h
o
d
o
lo
gy
 
58 
 
SDS equilibration buffer solution  
(6 M urea, 75 mM Tris-HCl pH 8.8, 29.3 % glycerol, 2% SDS, 0.002% 
Bromophenol blue) 
 
Urea, 72.1 g, Tris-HCl pH 8.8, 10ml, 87% (w/w) glycerol, 69 ml, and 1% 
Bromophenol blue stock solution, 400 µl, were mixed and double-distilled water was 
added to make up 200 ml. SDS equilibration buffer A was prepared by adding 0.1 g of 
DTT in 10 ml of SDS equilibration buffer solution. SDS equilibration buffer B was 
prepared by adding 0.25 g of iodoacetamide in 10 ml of SDS equilibration buffer 
solution. 10 ml of solution was prepared per IPG strip. 
 
10X Laemmli SDS electrophoresis buffer  
(250 mM Tris-base, 1.92 M Glycine, 1% SDS) 
 
Tris-base, 30 g, glycine, 144.1 g, and 10 g of SDS were mixed and double-
distilled water was added up to one litre. This buffer was diluted by one time for 2-DE. 
 
Monomer stock solution 
(30% Acrylamide, 0.8% N,N’-methylenebisacrylamide) 
 
Acrylamide, 300 g and N, N’-methylenebisacrylamide, 8 g, were mixed and 
double distilled water was added to make up one litre. This solution was kept in dark 
bottle at 4°C.  
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4 X Resolving gel buffer solution (1.5 M Tris-base, pH 8.8) 
Tris-base, 181.7 g, was diluted in 750 ml of double-distilled water and the pH of 
the solution was adjusted to 8.8 using concentrated HCl. After that, double-distilled 
water was added to make up to one litre. This solution was stored at 4°C. 
 
Bromophenol blue stock solution 
(1% Bromophenol blue, 0.6% Tris-base) 
 
Bromophenol blue, 0.1 g, and Tris-base, 0.06 g, were mixed and double-distilled 
water was added to make up to 10 ml. This solution was kept in aliquots at 4°C. 
 
10% w/v SDS solution 
SDS, 5 g, was dissolved in 50 ml of double-distilled water. Solution may be 
stored at room temperature. 
 
10 % APS solution 
APS, 0.1 g, was dissolved in 1 ml of double-distilled water. This solution was 
prepared prior to use.  
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Agarose sealing solution  
(25 mM Tris base, 192 mM glycine, 0.1% SDS, 0.5% agarose, 0.002% 
bromophenol blue) 
 
Laemmli SDS electrophoresis buffer, 100ml, agarose, 0.5 g, and 200 µl of 1% 
bromophenol blue stock solution were mixed together and heated in the microwave. 
After all the agarose had dissolved, the solution was stirred until it is cooled and later 
stored. During the equilibration step, the agarose sealing solution can be reheated three 
to five minutes before use. 
 
Overlaying solution (water saturated-butanol) 
n- butanol or t- butanol, 50 ml, was mixed with 5 ml of double-distilled water. 
 
Gel storage buffer 
4 X resolving buffer solution, 250 ml, and 10ml of 10% SDS was mixed and 
double-distilled water was then added up to one litre. This solution is sufficient to store 
six sets of glass plates containing the polymerized gels. The gels were immersed with 
this buffer and kept in 4°C until used. Usually, this solution was replenished after third 
times of usage.  
 
 
 
 
 C
h
ap
te
r 
3
: M
et
h
o
d
o
lo
gy
 
61 
 
3.10.2 Rehydration of IPG Drystrip 
Protein concentrations of sera samples were done by using BCA
TM 
Protein 
Assay Kit (as mentioned in section 3.8). A specified volume of serum sample that 
contain 200 µg/ml proteins, was mixed with the urea rehydration buffer containing 10% 
DTT up to 900µl. Only 450 µl of the sample solution (which contains approximately 
100 µg/ml protein) were used in the rehydration process. 450 µl of the solution were 
taken out from the tube and pipetted in the well of the reswelling tray (GE Healthcare 
Bioscience). Then, the immobiline dry strip (pH 4-7, 24 cm) were laided on the solution 
with the gel surface facing down the well surface. After all the solution covered the 
entire strip and all the bubbles were removed, the IPG Drystrip was overlaid with 
PlusOne Drystrip Cover Fluid to prevent crystallization of the urea. The rehydration 
process was left for 20 hours to ensure the entire IPG Drystrip was fully rehydrated. 
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3.10.3 First Dimension Gel Electrophoresis (isoelectric Focusing) 
After rehydration, the IPG Drystrip was subjected to 1
st
 dimension 
electrophoresis using IPGphor III (GE Healthcare Bioscience). The strip was taken out 
from the reswelling tray carefully using a forcep and the excessive oil was removed by 
gently dabbing the strips on a damp filter or tissue paper. The strip was then transferred 
on the silica plate assembled in the IPGphor III with the gel surface facing up. The 
positive side of the strip positioned on the positive side of the IPGphor III and vice 
versa. The damp paper wicks were placed on both ends of the strip and followed by the 
assembly of electrodes. In this process, up to 12 strips can be run at the same time.  
First gel dimension electrophoresis was run for 18 hours with the total voltage of 
75 kV/Hrs. The specific process of 1
st
 dimension electrophoresis was performed as 
follows: 
 S1: Step and Hold  500V  1:00 Hr 
  S2: Gradient  1000V  7:00 Hrs 
  S3: Gradient  8000V  3:00 Hrs 
  S4: Step and Hold  8000V  7:10 Hrs or  
                                                                                           Until reach 75 kV/Hrs 
After the iso-electric Focusing (IEF) process was completed, the strips were 
rinsed with milli-Q water to remove the PlusOne drystrip cover fluid. The strip was 
stored in an equilibration tube with the support film facing towards the wall of the tube. 
The strip can be transferred directly to the 2
nd
 dimension electrophoresis by performing 
equilibration step or can be stored in -80⁰C freezer. 
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3.10.4 IPG strip equilibration 
 The equilibration step is required to saturate the IPG strip with the SDS buffer 
for protein separation in second dimension electrophoresis (2-DE). Equilibration 
procedure involves two equilibration steps. The first equilibration step requires 100 mg 
DTT per 10 ml SDS equilibration buffer (buffer A) and the second equilibration step 
requires 250 mg iodoacetamide per 10 ml SDS equilibration buffer (buffer B). These 
solutions were prepared prior to use. IPG strips were placed in individual tubes with the 
support film facing towards the wall. Then, 10 ml of buffer A was added to each tube. 
Tubes were capped and placed on the shaker. The strips were equilibrated for 15 
minutes. After the first equilibration, buffer A was removed and buffer B was then 
added subsequently. The second equilibration step was continued for 15 minutes and the 
solution was then removed.  
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3.10.5 Second Dimension Gel Electrophoresis (2-DE) 
3.10.5.1 Preparation of 11% second dimension gel 
Eleven percent of second dimension gel was prepared according to Table 3.4. 
All the solutions were added in a beaker and were mixed by slow stirring. 10% APS 
solution was freshly prepared and added just prior to use and TEMED was added last. 
Usually, the 11% second dimension gel was prepared a day before the electrophoresis. 
Once the solution is ready, the solution was poured slowly on the top of gel caster 
channel until it reached approximately 0.5 cm from the top of the gel plate. Then, water 
saturated butanol was laid slowly on the solution using a dropper. The solution was 
allowed to polymerize for a minimum of one hour.  
 After all the gels have polymerised, the gel plate was disassembled from the gel 
caster. Each gel plates were rinsed with milliQ water to remove all the water saturated 
butanol. Then, the gels were kept in the storage solution at 4°C. 
 
Table 3.4: The preparation of 2-DE gel. 
Solution Volume (ml) 
 
Monomer solution (30% Acrylamide, 0.8% N,N’-
methylenebisacrylamide) 
 
37.0 
4X resolving gel buffer (1.5 M Tris Base, pH 8.8) 25.0 
Double distilled water 36.5 
10 % SDS 0.5 
10 % ammonium persulfate 1.0 
TEMED 0.033 
    Note: This preparation is sufficient for six 26 X 28 cm 2-DE gels. 
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3.10.5.2 Second Dimension Electrophoresis  
 In second-dimension electrophoresis step, firstly, equilibrated strips were rinsed 
with SDS electrophoresis buffer to lubricate it. Then, the strips were placed onto the 
surface of second-dimension gel and any formation of bubbles in between the strip and 
the second-dimension gel were removed for a perfect migration. After all the bubbles 
were removed, the strip was sealed with agarose sealing solution. Electrophoresis (Ettan 
Daltsix electrophoresis unit [GE Healthcare Bioscience]) was performed at a constant 
power in two steps using Electrophoresis Power Supply – EPS 601 (GE Healthcare 
Bioscience). The electrophoresis conditions were set as follows, at the temperature 
25⁰C: 
Step µA/gel Voltage Time 
(Hr:Min) 
Walt/gel 
S1 10 80 1:0 1 
S2 40 500 4:30 – 6:30 13 
 
The electrophoresis was terminated when the dye front reached approximately 1 cm 
from the bottom of the gel. After electrophoresis, gels were removed from their 
cassettes in order to prepare for staining.  
  The cassette was immersed in milliQ water and the cassette was opened at the 
end of cassette slowly. After the upper cassette was released from the gel, the strip was 
taken out and placed in a container filled with fixing solution. Then, small upper end of 
positive side of the gel was marked by a slant cutting. Next, the gel were taken out 
gently by holding both upper side of the gel and transferred into the same container as 
its strip.  
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3.10.6 Silver staining  
 The gel was immersed in the fixing solution individually. The recipe and 
protocol used for each silver staining step were done as follows. Approximately 500 ml 
of solution was required for each gel.  
 During the staining procedure, the removal of solution was done similarly as in 
section 3.9.5. However, in this procedure, more precaution is required due to its larger 
size of gel.  
Table 3.5: Silver staining procedure 
Step Solutions Amount Time 
Fixation Ethanol 
Acetic acid, glacial 
ddH2O make up to 500 ml 
200 ml 
50 ml 
Overnight 
Sensitizing Ethanol 
25% w/v Glutardialdehyde 
Sodium thiosulphate 
Sodium acetate trihydrate  
ddH2O to make up 500 ml 
150 ml 
2.5 ml 
1.0 g 
34.0 g 
30 minutes 
Washing Double distilled water  3 X 5 minutes 
Silver reaction Silver nitrate solution 
37% w/v Formaldehyde 
ddH2O to make up 500 ml 
1.25 g 
0.2 ml 
20 minutes 
Washing Double distilled water  2 x 1 minute 
Developing Sodium carbonate 
37% w/v Formaldehyde 
5% w/v Sodium 
thiosulphate 
ddH2O to make up 500 ml 
12.5 g 
0.2 ml 
14 µl 
4 minutes 
Stop EDTA-Na2 H2O 
ddH2O make up to 500 ml 
7.3 g 10 minutes 
Washing Double distilled water  3 X 10 minutes 
 Note: The fixation steps may be prolonged up to three days if desired for convenience.  
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The use of glutarylaldehyde in sensitizing step and formaldehyde in silver reaction 
solution were omitted as well as preserving solution if the gel was to be subjected to MS 
analysis. 
 
 
3.10.7 2-DE gels protein spots analysis 
 
 The 2-DE gels were scanned using ImageScanner III (GE Healthcare 
Bioscience) and analyzed using Image Master Platinum 7.0 Software (GE Healthcare 
Bioscience). The spots were then finally analyzed based on the Matched Number and 
the significant value with ANOVA (p < 0.05). Significant value obtained from the 
software was normalized using Excell ANOVA (p < 0.05). The expression dynamic of 
protein spots for nontreated SHR, treated SHR and normotensive rats were calculated 
and compared based on respective percentage of volume (% volume) obtained from the 
software. Significant spots were selected for identification using MALDI-TOF/TOF. 
After the protein ID was obtained, the expression dynamic of the identified spot was 
observed to find the possible relationship with hypertension by comparing with several 
reported journals. 
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3.11 MALDI-TOF/TOF mass spectrometry 
 
3.11.1 Reagents preparation 
 
100 mM Ammonium bicarbonate 
Ammonium bicarbonate, 0.791 g, was dissolved in double distilled water 
(ddH2O) to make up 100 ml. 
 
Destaining solution (15 mM Potassium fericyanide; 50mM Sodium thiosulphate) 
Potassium fericyanide, 0.1 g, and 0.25 g of sodium thiosulphate was dissolved in 
ddH2O to make up 20 ml. 
 
Reducing solution (10 mM DTT in 100 mM ammonium bicarbonate) 
DTT, 0.0308 g, was dissolved in 100 mM ammonium bicarbonate to make up 20 
ml. This solution was prepared prior to use. 
  
Alkylating solution (55 mM iodoacetamide in 100 mM ammonium bicarbonate) 
Iodoacetamide, 0.2036 g, was dissolved in 100 mM ammonium to make up 20 
ml. This solution was prepared  prior to use. 
 
Washing solution (50% acetonitrile [ACN] in 100 mM ammonium bicarbonate) 
Absolute ACN, 20 ml, was diluted with 100 mM ammonium bicarbonate to 
make up 40 ml. 
 
Dehydrating solution 
100% or absolute ACN was directly used in this step.  
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Digestion solution  
(7 ng/ml of trypsin in 40 mM ammonium bicarbonate in 10% ACN) 
1 µg/ml trypsin, 5 µl, was dissolved with 709 ml of 40 mM ammonium 
bicarbonate in 10% ACN. 
 
40 mM ammonium bicarbonate in 10% ACN 
 Ammonium bicarbonate, 0.316 g, was dissolved in 100 ml of 10% ACN. 
 
10% ACN 
ACN 10 ml was diluted to make up 100 ml. 
 
 
Solutions for Zip-Tip (desalting) procedure: 
Wetting solution 
100% ACN was directly used in this step. 
 
Equilibration solution (0.1% Formic acid in ddH2O) 
Formic acid (98%-100%), 20 µl, was diluted with 19.98 ml of ddH2O. 
 
Elution solution (0.1 % Formic acid in 50% ACN) 
Formic acid (98%-100%), 20 µl, was diluted with 19.98 ml of 50% ACN. 
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Matrix solution (10 mg/ml of α-cyano-4-hydroxy-cinnamic acid) 
α-cyano-4-hydroxy-cinnamic acid, 10 mg, was dissolved with 40% of buffer A 
and 60% of buffer B. 
a) Buffer A (2% ACN; 0.1% TFA) 
ACN, 2 ml, and 0.1 ml of TFA were mixed with 100 ml of milliQ water. 
b) Buffer B (98% ACN ; 0.1% TFA) 
ACN, 98ml, and TFA, 0.1 ml, were mixed with 100 ml of milliQ water. 
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3.11.2 MALDI-TOF/TOF analysis - digestion procedure 
 Protein selected from image master analysis based on the dynamic expression 
and significance was picked from preparative gel. This gel was previously loaded with 
300 µg/ml of protein. Three gels were prepared for the MALDI-TOF/TOF. The protein 
spots of interest were picked by using clean eppendorf tips (size 5000 μl). Each gel plug 
was individually stored in labelled eppendorf microcentrifuge tubes and kept in 4⁰C 
freezer until use. Clean handling is required in this step to avoid contamination from 
human keratin. Procedure for proteolytic digestion using trypsin is shown in Table 3.5. 
Gel plug in microcentrifuge tubes were immersed with destaining solution for 30 
minutes. Then, the destaining solution was carefully removed and replaced with 
reducing solution. The next steps were conducted according to Table 3.5. In digestion 
step, 7 ng/ml of trypsin solution was used to immerse the gel plug for one night. On the 
next day, the trypsin solution (containing digested protein in fragments) was transferred 
to a new and clean tube. The gel plug was then extracted twice and the extraction 
solutions were dispensed into the same tube. The solutions in the tube were dehydrated 
in speed-vacuum for one hour in low heat condition. After the solutions were fully 
dehydrated and produced white powder, the equilibration solution was added and shook 
continuously for 15 minutes. Along the process, non-powdered gloves were used and 
wiped with 70% ethanol to remove keratin and other contaminant. The extracted peptide 
was then desalted using ZipTip
®
 procedure (Appendix E).  
 
 
 
 
 
 
 
Note: During staining procedure for MALDI-TOF/TOF analysis, glutaraldehyde in sensitizing step and 
formaldehyde in silver reaction were omitted. 
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Table 3.6: Tryptic digestion procedure prior to mass spectrometry analysis. 
 
Methods was cited from Shevchenko et al. (2007) with some modifications 
 
 
 
Procedure / Steps Duration 
Destaining step 
50 µl of 15 mM Potassium ferricyanide in 50 mM sodium 
thiosulphate 
 
30 minutes 
Reducing step 
150 µl of 10 mM Dithiothreitol in 100 mM ammonium 
bicarbonate  
 
30 minutes 
Alkylating step 
150 µl of 55 mM iodoacetamide in 100 mM ammonium 
bicarbonate 
 
20 minutes 
Washing step 
500 µl of 50% ACN in 100 mM ammonium bicarbonate 
3 X 20 minutes 
(shaking) 
Dehydrating step 
50 µl absolute ACN   
15 minutes 
(dry in speedvac) 
Digesting step 
30 µl of 7 ng/µl Trypsin in 40 mM ammonium bicarbonate in 
10% ACN 
 
Overnight, 37°C 
Extraction I 
50 µl of 50% ACN 
 
15 minutes 
Extraction II 
50 µl of 100% ACN 
 
15minutes 
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3.11.3 MALDI-TOF/TOF mass spectrometry analysis and database searching 
Extracted peptides were desalted using ZipTip C18 (Millipore, USA) according 
to protocol described by the manufacturer. The final elution volume following ZipTip 
cleanup was 1.5µl. The peptides samples were then mixed (1:1) with a matrix consisting 
of a saturated solution of CHCA (α-cyano-4-hydroxycinnamic acid, Sigma) prepared in 
50% ACN/0.1% TFA. Aliquots of samples (0.7µl) were spotted onto stainless-steel 
sample target plates. Peptide mass spectra were obtained by MALDI-TOF/TOF mass 
spectrometer (AB4800 plus, Applied Biosystems) in the positive ion reflector mode. For 
precursor ion selection, all fractions were measured in single MS before MS/MS was 
performed. For MS/MS spectra, the peaks were calibrated by default. The 20 most 
abundant precursor ions per sample were selected for subsequent fragmentation by 
high-energy CID. The collision energy was set to 1 keV and air was used as collision 
gas. The criterion for precursor selection was a minimum S/N of 5. The mass accuracy 
was within 50 ppm for the mass measurement and within 0.1 Da for CID experiments. 
The other parameters settings for search were; trypsin, 1 missed cleavage, variable 
modification of carbamidomethyl, oxidation of methionine, peptide charge of 1+, and 
monoisotopic. For database searches, known contamination peaks such as keratin 
omitted and analyzed by the Global Protein Server Explorer 3.6 Software (Applied 
Biosystems). This uses an internal MASCOT (Matrix Science, UK) program for 
matching MS and MS/MS data against database information. The data obtained were 
screened against Rodentia databases downloaded from the Swiss-Prot/TrEMBL 
homepage (http://www.expasy.ch/sport). All the MALDI-TOF/TOF analysis was 
performed at least twice to confirm the identified protein. 
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3.12 SELDI-TOF mass spectrometry 
  
3.12.1 Preparation of reagents / solutions 
 
ProteinChip CM low stringency buffer (0.1 M Sodium acetate, pH 4.0) 
 ProteinChip CM low stringency buffer was purchased from Bio-Rad 
Laboratories. This buffer was used throughout SELDI-TOF sample preparation 
procedure. Buffer was stored at 11°C.  
 
Matrix solvent (50% (v/v) ACN, 0.5% (v/v) TFA) 
 ACN, 200 µl and TFA, 2 µl was dissolved in 198 µl of water. This solvent was 
freshly prepared.  
 
Matrix [α-Cyano-4-hydroxycinnamic acid (CHCA)]  
 α-Cyano-4-hydroxycinnamic acid (CHCA), 5 mg, was dissolved in 200 µl of 
matrix solvent and vortex for two minutes. The matrix was spun at 1,000 x g for one 
minute. Supernatant was transferred into new microcentrifuge tube and kept in the dark. 
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3.12.2  Sample preparation and analysis 
 ProteinChip CM-10 was used in this experiment. ProteinChip arrays were 
inserted into array cassette and placed onto the bioprocessor in the correct orientation. 
Spots were equilibrated with the addition of 150 µl of buffer in each well for five 
minutes with vigorous shaking. Buffer was then removed from the wells. Pre-washing 
step was then continued with 150 µl of buffer for five minutes. This step was repeated 
twice. The pre-washing solution was removed and replaced with 100 µl of sample (10 
times dilution). The sample was incubated for 30 minutes in a humidified chamber with 
constant shaking. During the sample application step, spots were not allowed to air-dry 
and any bubbles on the spot were removed. Diluted sample was then removed and each 
spot was then washed with 150 µl of buffer with constant shaking for five minutes. 
Washing step was repeated three times. 200 µl of milliQ water was immediately added 
and removed to rinse the spot twice. ProteinChips were allowed to semi-dry in room 
temperature before the addition of 2 µl of matrix. The arrays were analyzed using the 
ProteinChip system using the following protocol setting (Table 3.6). 
 
Table 3.7: Protocol setting for SELDI-TOF analysis 
Acquisition setting 
Mass range 0 – 40,000 Da 
Focus mass 10, 000 Da 
Matrix attenuation 500 Da 
Sampling rate 800 MHz 
Laser energy 960 nJ 
Shots kept 795 
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3.12.3 SELDI spectra analysis 
3.12.3.1 Univariate analysis 
 Statistical analysis was performed using the ProteinChip Data Manager 3.5 (Bio-
Rad Laboratories, Inc). Peaks with m/z values < 2.5 kDa were excluded from the 
analysis as these peaks were mainly ion noise from the matrix. For Expression 
Difference Map (EDM) analysis, spectra were compiled and qualified peak mass signal 
peaks with mass-to-charge ratios (m/z) between 2.5-40 kDa were auto-detected. Peak 
clusters were completed using second-pass peak selection with S/N > 2, within 0.1% of 
mass window and allowing estimated peaks to be added. p-values were determined 
using mean peak intensities from triplicate samples with p<0.05 considered as 
significant. 
 
3.12.3.2 Multivariate analysis 
 For determination of possible biomarker, Biomarker Pattern Software™ (Bio-
Rad Laboratories Inc.) was used. Different groups were used in this analysis for 
comparison between different treatments. 
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4.0 Results 
4.1 Angiotensin Converting Enzyme (ACE) Inhibitory Assay 
 ACE inhibitory activity was determined by measuring the product; hippurate, 
produced in the experiment. The formation of hippurate-cyanuric chloride complex was 
calculated by comparing the absorbance value at 382 nm against the hippurate standard 
curve shown in Figure 4.1.  
From the study (section 3.6.3), both fruit (SF) and big leaves type (BL) of F. 
deltoidea extracts showed significant inhibitory effect towards ACE activity as the p -
values obtained from one way ANOVA were 2.51 X 10
-7 
and 4.23 X 10
-6 
respectively. 
Figure 4.2 and 4.3, showed the inhibition of SF and BL were increased in parallel to the 
increase of extracts concentrations. Results from this assay indicated the half maximal 
inhibitory concentrations (IC50) of SF and BL extracts obtained are 0.13 ± 0.023 mg/ml 
and 0.18 ± 0.023 mg/ml as shown in Table 4.1. The two way ANOVA statistical 
analysis revealed no significant difference between the two treatments. Therefore, both 
extracts were equally good ACE inhibitors with no significant difference in terms of 
their effectiveness.     
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Figure 4.1:  Hippurate standard curve obtained from ACE assay. The p-value 
obtained from ANOVA analysis is 1.84X10
-18
. 
 
 
 
Figure 4.2:  Percentage of ACE inhibition with SF extract. From the ANOVA 
statistical analysis, the p-value = 2.51X10
-7
. 
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Figure 4.3:  Percentage of ACE inhibition with BL extracts treatment. From the 
ANOVA statistical analysis, the p-value = 4.23X10
-6
. 
 
 
 
Table 4.1: The half maximal inhibitory concentration (IC50) of SF and BL extracts 
with S.E.M. From two-way ANOVA statistical analysis, p = 0.401427. 
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Concentration of BL extract 
Sample IC50 (mg/ml) 
Small fruit extract (SF) 0.13 ± 0.023 
Big Leave extract (BL) 0.18 ± 0.023 
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4.2 SDS-PAGE 
 SDS-PAGE serum protein profile is shown in Figure 4.4. The changes in serum 
protein profile could be observed in three molecular weight (MW) regions as shown in 
Figure 4.5a-c.  
From the SDS-PAGE analysis, treatment with F. deltoidea extracts caused 
differential expression of serum protein bands in three regions, 6.9 kDa, 29 kDa and 
35.8 kDa (Table 4.2). Several protein bands exhibited differences in their expression as 
compared with other treatments. 
In MW region 35.8 kDa (Figure 4.5a), the protein expression profile from SHR 
treated (SF, BL and captopril) exhibited a reversed pattern compared  to  nontreated 
SHR. The pattern demonstrated changes towards a similar profile as normotensive. 
However, protein profile from the serum obtained from SHR treated with captopril did 
not show much difference from the serum protein profile obtained from the non-treated 
SHR. 
In MW region 29 kDa (Figure 4.5b), similar protein profiles were found in all 
treatments and control, normotensive rats group. Differences were only observed in 
terms of their intensities. 
In MW region 6.9 kDa (Figure 4.5c), only the serum profiles of SHR-SF and 
SHR-Cp exhibited similar profile with normotensive rats. SHR treated with BL 
however; did not express reversed pattern but showed rather similar pattern as in 
nontreated SHR.  
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Table 4.2: Differentially expressed protein bands found in SDS-PAGE in three 
MW regions. 
 
MW region 35.8 kDa MW region 29 kDa MW region 6.9 kDa 
52.60 ± 1.57 kDa 30.20 ± 0.41 kDa 8.67 ± 0.40 kDa 
44.05 ± 1.10 kDa 23.70 ± 0.40 kDa 8.60 ± 0.68 kDa 
  8.06 ± 0.32 kDa 
  7.23 ± 0.28 kDa 
 
 
 
 
Figure 4.4: Serum protein profile separated in12.5% acrylamide gel.  
 
Blue circles indicated the MW regions where the differences of protein profiles in 
different treatments were observed. (A) MW region for 35.8 kDa, (B) 29 kDa and (C) 
6.9 kDa respectively. 
L1 - serum from normotensive rat; L2 - nontreated SHR (SHR); L3 - SHR treated with 
SF (SHR-SF); L4 - SHR treated with BL (SHR-BL); L5 - SHR treated with captopril 
(SHR-Cp); L5 - pre-stained MW standards with specific molecular weight from 6.9-210 
kDa. 
 
 
   L1             L2                   L3                  L4                   L5            L6 
A 
B 
C 
  
C
h
ap
te
r 
4
: R
e
su
lt
s 
 
82 
 
a 
 
 
 
  
b 
 
 
 
c 
 
 
 
Figure 4.5 a-c: Serum protein profiles in different MW regions exhibiting the 
protein bands affected by the different treatments.  
Different administration of both SF and BL of F. deltoidea exhibited protein alterations 
at various MW regions; 35.8 kDa (a), 29 kDa (b) and 6.9 kDa (c). Data showed the MW 
of the protein bands with its standard deviations. 
 
 
 
 
 
52.60 ± 1.57 kDa 
44.05 ± 1.10 kDa 
30.20 ± 0.41 kDa 
23.70 ± 0.4 kDa 
8.67 ± 0.4 kDa 
8.60 ± 0.68 kDa 
8.059 ± 0.32 kDa 7.23 ± 0.28 kDa 
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4.3 2-DE Gel Electrophoresis  
 Serum protein profile of F. deltoidea (SF and BL extracts) treated with SHR 
were compared between 8-10 weeks old normotensive rats, nontreated SHR and SHR 
treated with SF and BL after ten days of treatment. SHR treated with captopril was used 
as the positive control. Normotensive rats represent normal healthy rats.  Representative 
rat serum proteome profiles from 2-DE are shown in Figure 4.6.  
 
Figure 4.6: Serum proteome profiles on IPGstrips pH 4-7 separated in 11% of 2-DE gels. 
100 µg/ml proteins were loaded onto the gels. The figure shows representative gels for 
normotensive rats (A), SHR/ disease (B), SHR-BL (C), SHR-SF (D) and SHR-Cp (E). 
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4.3.1 Proteome Analysis Using Image Master Platinum 7 software 
 Protein spots visualized by silver staining in normotensive rat, nontreated SHR, 
SHR-SF, SHR-BL and SHR-C gels were analysed using Image Master Platinum 7 
software. The software facilitated identification of significantly differentially expressed 
proteins based on percentage volume of individual protein spots. Individual spots in all 
groups were then matched with each other to observe the protein expression dynamics. 
The statistical analysis of percentage of volume of individual spots obtained from the 
software was normalised using Excel ANOVA. Only spots with ANOVA p < 0.05 were 
deemed as significantly different and were selected for protein identification using 
MALDI-TOF/TOF. However, to further improve the power of testing while maintaining 
control over a meaningful measure of error, we have calculated the false discovery rate 
(FDR) by using the Benjamin and Hochberg method (Benjamini & Hochberg, 1995). 
From Image Master analysis, approximately 1000 protein spots were detected in each 
sample - normotensive rats (1238 ± 110), nontreated SHR (909 ± 63), SHR-SF (1077 ± 
36), SHR-BL (1020 ± 42) and SHR-Cp (1010 ± 92). From the matched gels, 1430 
matching spots were found in those groups (Normotensive rats vs nontreated SHR vs 
SHR-SF vs SHR-BL vs SHR-Cp). Statistical analysis from ANOVA confirmed that 12 
matched spots were found to be significantly different in their expression (Figure 4.7). 
Based on the Benjamin and Hochberg procedure, at this level, only seven spots were 
significant. 
In our study, the expression dynamic of protein spots in treated SHR rats (SHR- 
SF and SHR-BL) were compared with the non-treated SHR rats (SHR) to better 
understand the effects of treatment on protein expression in serum. The percentage of 
volume for the significantly different spots in different groups are shown in Table 4.3 
and the calculated fold changes of expression dynamic are shown in Table 4.4. 
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Figure 4.7: A representative of silver-stained 2-DE gel image of rat serum 
proteome profile.  
Gel was loaded with 100 μg protein and were separated using IPG strip pH 4-7. 
Identified protein spots that showed significant difference in their expression compared 
to normal and nontreated SHR rats are numbered. All the numbering is obtained from 
gel analysis using Image Master Platinum 7.0 Software.  
pH 7 pH 4 
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Table 4.3: Percentage volume of protein spots that are significantly different in expression.  
  
 
 
 
 
 
 
 
 
 
Percentage of spot volume obtained from the Image Master Platinum 7.0 Software was used in the comparison of protein expression. SHR-SF: SHR 
treated with SF extract, SHR-BL: SHR treated with BL extract, SHR Cp: SHR treated with captopril, SD: Normotensive rat, SHR: nontreated SHR 
rats. 
 ** spots with ANOVA p-value <0.01.                ϒ exhibited significance in FDR analysis. 
Spot No Normotensive SHR SHR-SF SHR-BL SHR-Cp p - value 
1 0.166963 0.068768 0.127979 0.099398 0.087419 0.020760 
50 0.072497 0.123245 0.113435 0.168048 0.120118 0.007999**ϒ 
69 0.124189 0.056224 0.044818 0.028093 0.028137 0.002392 
85 0.008403 0.029586 0.026316 0.051608 0.025363 6.27 x 10
-4
** ϒ 
96 0.009116 0.043230 0.087596 0.028094 0.024504 0.008829**ϒ 
99 0.179683 0.243203 0.301891 0.469338 0.293398 0.001826** ϒ 
108 0.246078 0.230608 0.279863 0.377688 0.287745 0.046979** ϒ 
117 0.080883 0.032488 0.058628 0.102981 0.064328 3.26 x 10
-5
** ϒ 
138 0.087800 0.046345 0.043946 0.094449 0.055478 0.021036 
211 0.348065 0.927473 0.535445 0.568058 0.173290 0.034403 
246 0.348065 0.335413 0.423150 0.448758 0.173290 0.001991 ϒ 
259 0.256395 0.192732 0.212440 0.315238 0.244894 0.040552 
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Table 4.4: The fold changes of the expression dynamic in different treatments 
compared to the diseased group. 
(+) indicates up-regulation of the protein, (-) indicates down-regulation of the protein.   
 
 
 
 
 
 
  
 
 
Spot No. Normotensive SHR-SF SHR-BL SHR-Cp 
1 +2.43 +1.86 +1.44 +1.27 
50 -1.70 -1.09 +1.36 -1.03 
69 +0.22 -1.25 -2.00 -2.00 
85 -3.52 -1.12 +1.74 -1.17 
96  -6.32 +2.03 -1.54 -1.77 
99 -1.35 +1.24 +1.93 +1.21 
108 +1.07 +1.21 +1.64 +1.25 
117 +2.49 +1.80 +3.17 +1.98 
138 +1.89 -1.05 +2.04 +1.20 
211 -2.66 -1.73 -1.63 -5.35 
246 +1.11 +1.26 +1.34 -8.35 
259 +1.13 +1.10 +1.64 +1.27 
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4.4  MALDI-TOF/TOF mass spectrometry 
Significant differentially expressed protein spots were then processed for 
identification by mass spectrometry (MALDI-TOF/TOF). All identified spots are shown 
in Table 4.5. From 12 spots, only one protein spot (Spot 96) was not identified. The 
remaining spots were identified as plasma retinol binding protein (RETBP), serum 
albumin precursor (ALBU), clusterin precursor (CLUS), complement c3 precursor 
(CO3), haptoglobin (HPT), alpha 1 macroglobulin (A1M), actin (ACTB), alpha 1 
antiproteinase (A1AT), alpha 2H glycoprotein (FETUA) and Apolipoprotein H 
(APOH). Spots 108 and 117 were both identified as A1M. Protein ID was accepted 
when the MOWSE protein score was more than the significance score suggested by the 
software (Figure 4.8).  
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Table 4.5:  The protein ID obtained from MALDI-TOF-TOF.  Shows the data acquired in the mass spectrometric analysis. 
Matched protein identity Spot Protein 
Abbreviation 
SwissProt 
Accession 
Number 
Theorotical 
(kDa/pI) 
Experimental 
(kDa/pI) 
MOWSE 
Protein 
score 
Sequence 
Coverage  
Peptide 
match 
Plasma retinol binding protein 1 RETBP P04916 23.2/ 5.69 10.8/6.51 596 45% 7 
Serum albumin precursor 50 ALBU P02770 68.7/6.09 19.9/5.21 82 16% 3 
Clusterin precursor (Sulfated 
glycoprotein 2) 
69 CLUS P05371 51.3/5.47 24.9/5.26 81 3% 1 
Complement C3  85 CO3 P01026 186.4/ 6.12 28.6/4.69 200 6% 5 
Haptoglobin precursor 99 HPT P06866 38.5/6.10 30.5/5.02 421 35% 6 
Alpha 1 macroglobulin precursor  108, 117 A1M P 01023 167.0/6.46 33.6, 36.2/ 
5.22,5.21 
547 10% 8 
Actin, cytoplasmic 1 (beta-actin) 138 ACTB P60711 41.7/5.29 36.2/5.56 280 23% 4 
Alpha 1 antiproteinase precursor 211 A1AT P 17475 46.1/ 5.70 58.2/5.00 609 20% 9 
Alpha 2HS glycoprotein 
precursor 
246 FETUA P 24090 37.9/ 6.05 65.2/5.15 237 14% 3 
Apolipoprotein H precursor  259 APOH P 26644 33.1/ 8.59 68.4/6.46 311 28% 9 
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Figure 4.8: The representative data (haptoglobin; spot 99) obtained from MALDI-TOF/TOF (A). The significant MOWSE score was determined 
by the software, circled in blue. Matched peptides of the peptide sequence are shown in bold red at the right of the figure (B).
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Peptide sequence Ion score Amino acid MOWSE score 
RETBP spot  
R.QEELCLER.Q + Carbamidomethyl (C) 22 174-181 
 
R.FSGLWYAIAK.K 
75 38-47 
K.YWGVASFLQR.G 61 108-117 
R.QRQEELCLER.Q + Carbamidomethyl (C 24 172-181 
R.LQNLDGTCADSYSFVFSR.D + 
Carbamidomethyl (C) 
147 140-157 
K.KDPEGLFLQDNIIAEFSVDEK.G 78 48-68 
R.LLSNWEVCADMVGTFTDTEDPAK.F + 
Carbamidomethyl (C) 
98 81-108 
ALBU spot 
K.LVQEVTDFAK.T 20 66-75 
 
K.DVFLGTFLYEYSR.R 39 348-360 
K.APQVSTPTLVEAAR.N 10 439-452 
   
   
   
    
Table 4.6: MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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Peptide sequence Ion score Amino acid MOWSE score 
CLUS spot  
R.QQSQVLDAMQDSFTR.A 76 167-181 
 
   
   
   
   
   
   
CO3  spot 
K.RQEALELIK.K 15 1042-1050 
 
K.KGYTQQLAFK.Q 16 1051-1060 
K.GYTQQLAFK.Q 47 1052-1060 
R.DICEGQVNSLPGSINK.A + Carbamidomethyl 
(C) 
72 1156-1171 
K.DFDSVPPVVR.W 33 1245-1254 
   
    
Table 4.6 (continued): MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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Peptide sequence Ion score Amino acid MOWSE score 
HPT spot 
K.VMPICLPSKDYVAPGR.M + Carbamidomethyl 
(C) 
37 203-218 
 
R.MGYVSGWGR.N 65 219-227 
K.YVMLPVADQEK.C + Oxidation (M) 51 239-249 
K.HTFCAGLTK.Y + Carbamidomethyl (C) 45 278-286 
K.SCAVAEYGVYVR.A + Carbamidomethyl (C) 69 321-332 
R.ATDLKDWVQETMAK.N 98 333-346 
    
Table 4.6 (continued): MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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Peptide sequence  Ion score Amino acid MOWSE score 
A1M spot  
R.LADLPGNYITK.V 65 1328-1338 
 
K.VNTLPLNFDK.A 
45 1369-1378 
K.VSGSGCVYLQTSLK.Y + Carbamidomethyl 
(C) 
68 1339-1352 
K.YNILPEAEGEAPFTLK.V 38 1353-1368 
K.MVSGFIPVKPSVK.K 89 1409-1421 
K.KLQDQSNIQR.T 60 1422-1431 
K.LQDQSNIQR.T 51 1423-1431 
R.TEVNTNHVLIYIEK.L 111 1432-1445 
ACTB spot 
R.AVFPSIVGRPR.H 36 29-39  
R.VAPEEHPVLLTEAPLNPK.A 69 96- 13 
R.GYSFTTTAER.E 33 197-206 
K.QEYDESGPSIVHR.K 85 360-372 
 
  
   
Table 4.6 (continued): MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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Peptide sequence Ion score Amino acid MOWSE score 
A1AT spot  
K.ISSNLADFAFSLYR.E 88 44 – 57 
 
  
 
K.NNYHSEAFSVNFADSEEAK.K 27 154 – 172 
K.NNYHSEAFSVNFADSEEAKK.V 103 154 – 173 
K.KVINDYVEK.G 33 173 - 181 
K.WKRPFNPEHTR.D 27 212 - 222 
K.RPFNPEHTR.D 34 214 – 222 
K.MQHLEQTLTK.D 50 278 – 287 
K.LSISGTYNLK.T 80 309 – 318 
R.VFNNDADLSGITEDAPLK.L 166 329 – 346 
FETUA  spot 
 
R.LGGEEVSVACK.L + Carbamidomethyl (C) 74 238 - 248 
R.HAFSPVASVESASGEVLHSPK.V 93 306 - 326 
K.VGQPGDAGAAGPVAPLCPGR.V 49 327 - 346 
   
   
Table 4.6 (continued): MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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Peptide sequence Ion score Amino acid MOWSE score 
APOH spot  
K.CTEEGKWSPELPVCAR.I + 2 
Carbamidomethyl (C) 
9 76 - 91 
 
 
 
K.WSPELPVCAR.I + Carbamidomethyl (C) 24 82 – 91 
R.ITCPPPPIPK.F + Carbamidomethyl (C) 48 92 - 101 
K.AVFGCHETYKLDGPEEVECTK.T  + 
2Carbamidomethyl (C) 
5 182 – 202 
K.LDGPEEVECTK.T  + Carbamidomethyl (C) 48 192 – 202 
K.KATVLYQGQR.V 47 222 – 231 
K.ATVLYQGQR.V 33 223 – 231 
K.KCSYTEEAQCIDGTIEIPK.C + 
2Carbamidomethyl (C) 
29 258 – 276 
K.EHSSLAFWK.T 67 280 - 288 
Table 4.6 (continued): MASCOT search results indicating the matched peptide sequence and the MOWSE score. 
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4.5  Identified proteins related to hypertension 
Seven proteins were found to be related to hypertension i.e. complement C3 
precursor (CO3), haptoglobin (HPT), alpha 1 macroglobulin precursor (A1M), alpha 1 
antiproteanase or alpha 1 antitrypsin (A1AT), Apolipoprotein (APOH), serum albumin 
precursor (ALBU) and retinol binding protein (RETBP).  
The 3D view image and expression dynamic of representative spots related to 
hypertensive protein are shown in Figures 4.9 – 4.15. The related spots are circled in 
green indicating the area measured in the analysis. The percentage volume for each spot 
was averaged and used to evaluate the expressions of the protein in different treatments.  
In this study, expression dynamic was calculated based on the ratio of 
percentage volume of the protein spots from 2-DE profiles of treated and non-treated 
SHR rats to monitor the effect of the extracts on hypertension.  
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4.5.1  Complement C3 (CO3) 
The expression of this protein in normotensive rats is down-regulated by three 
folds compared to SHRs. Treatment with SF caused normalization of the aberrant 
expression of CO3 in SHR. CO3 expression in SHR-SF showed reversed pattern after 
the treatment as shown in Table 4.4 and Figure 4.9. However, treatment with BL 
extracts caused proportional increase of CO3.  
Protein identification (ID) in MALDI-TOF/TOF exhibited significant score with 
a MOWSE score of 200 with 6% matched peptides. The matched peptides were 
observed between positions 1042 to 1254 of the protein sequence (Table 4.6). 
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Figure 4.9: The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for CO3.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL 
extract. Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.  
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4.5.2  Haptoglobin (HPT) 
The expression of HPT in normotensive rats was down-regulated 1.35 fold as 
compared to SHRs.  Treatments with these extract (SF and BL) caused significant 
increase of the expression of haptoglobin in SHR. The protein expression of HPT in 
treated rats increased 1.24 and 1.92 fold as compared to SHRs as shown in Table 4.4 
and Figure 4.10.  
Protein identification (ID) in MALDI-TOF-TOF exhibited significant score with 
a MOWSE score of 421 with 35% matched peptides. Matched peptides were observed 
between positions 37 to 98 of the protein sequence (Table 4.6). 
 
  
C
h
ap
te
r 
4
: R
e
su
lt
s 
 
101 
 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
A
ve
ra
ge
 p
er
ce
n
ta
ge
 o
f 
vo
lu
m
e
 
 s
p
o
ts
  
 
Expression of spot 99 
(haptoglobin) 
 
Normotensive  
SHR 
SHR-SF 
SHR-BL 
 
                       
                                                   
                                 
         
Figure 4.10:  The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for HPT.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.  
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4.5.3  Alpha 1 macroglobulin (A1M) 
Two protein spots were identified as A1M; spots 108 and 117. The fold changes 
of normotensive and SHR-BL compared to SHRs was up-regulated 1.12 and 2.04 fold 
respectively. However, SHR-SF was down-regulated 1.13 fold compared to SHRs.  
 Along the treatment, all the treatments showed up-regulation of protein 
expression in normotensive rats, SHR-SF and SHR-BL with fold changes of 2.49, 1.80 
and 3.17. The expression of protein spot 117 (alpha 1 macroglobulin) can be observed 
in Table 4.4 and Figure 4.11.  
Protein identification (ID) by MALDI-TOF-TOF exhibited significant score 
with 541 MOWSE score and 10% matched peptides. The peptides matched were 
observed between position 1328 to 1445 of the protein sequence (Table 4.6). 
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Figure 4.11:  The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for A1M.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.  
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4.5.4  Serum albumin (ALBU) 
The expression of ALBU in SHR-SF and normotensive rats was down-regulated 
by 1.08 and 1.70 fold compared to SHRs. However, SHR-BL exhibited a contrary 
effect. Treatment with SF caused normalization of the expression of ALBU in SHR as 
shown in Table 4.4 and Figure 4.12. However, treatment with BL extracts caused a 
proportional increase of ALBU.  
Protein identification by MALDI-TOF/TOF exhibited significant score with a 
MOWSE score of 82 and 16% matched peptides. The matched peptides were observed 
at positions 66-75, 348-360 and 439-452 of the protein sequence (Table 4.6). 
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Figure 4.12:  The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for ALBU fragment.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.
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4.5.5  Alpha 1 antiproteinase or Alpha 1 antitrypsin (A1AT) 
The expression of A1AT in normotensive rats was down-regulated 2.66 fold 
compared to SHRs. Treatment with SF and BL caused normalization of the aberrant 
expression of A1AT in SHR. The expression of this protein was decreased by 1.73 and 
1.63 folds in SHR-SF and SHR-BL respectively (Table 4.4 and Figure 4.13).  
Protein identification by MALDI-TOF-TOF exhibited significant score with a 
MOWSE score of 609 and 20% matched peptides. The matched peptides were observed 
between positions 44 to 346 of the protein sequence (Table 4.6). 
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Figure 4.13:  The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for A1AT.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software. 
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4.5.6 Apolipoprotein H (APOH) 
The expression of APOH in normotensive rat, SHR-SF and SHR-BL was up-
regulated by 1.13, 1.10 and 1.64 fold compared to SHRs. Treatment with SF and BL 
caused normalization of the aberrant expression of APOH in SHR as shown in Table 4.4 
and Figure 4.14.  
Protein identification by MALDI-TOF-TOF exhibited significant score with a 
MOWSE score of 311 and 28% matched peptides. The matched peptides were observed 
between positions 76 to 288 of the protein sequence (Table 4.6).  
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Figure 4.14:  The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for APOH.  
(A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.  
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4.5.7 Plasma retinol binding protein (RETBP) 
The expression RETBP in normotensive rat, SHR-SF and SHR-BL was up-
regulated by 2.43, 1.86 and 1.45 fold compared to the SHRs. The expression of RETBP 
in SHR-SF and SHR-BL was increased after the treatment as compared to SHRs. 
Treatment with SF and BL caused normalization of the expression of RETBP in SHR as 
shown in Table 4.4 and Figure 4.15.  
Protein identification by MALDI-TOF-TOF exhibited significant score with a 
MOWSE score of 596 and 45% matched peptides. The matched peptides were observed 
between positions 38 to 181 of the protein sequence (Table 4.6). 
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Figure 4.15: The 3D view of protein expression obtained from Image Master Platinum 7.0 Software for RETBP.  
A) Representative spot 3D view for normotensive rat, (B) nontreated SHR rat, (C) SHR-treated with SF extract, (D) SHR treated with BL extract. 
Histogram shows the the average of spot percentage of volume obtained from the quantitaive analysis using the software.  
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4.6  SELDI-TOF mass spectrometry 
 Sera from rat treated with F. deltoidea aqueous extracts were examined using 
CM-10 arrays to monitor alterations of any native proteins in  the serum proteome. 
SELDI analysis produced spectra with peaks representing low MW serum proteins. 
Peaks labeling was performed by the Chipergen Express Data Manager in the Ciphergen 
Protein Software 5.0. The amount of individual serum proteins were estimated based on 
the peak intensity of the mass spectral signal. The mass/charge ratio (m/z) obtained 
from the analysis is equivalent to the molecular weight of each protein. Two analyses 
were performed in this study i.e. univariate analysis and multivariate analysis. 
Univariate analysis is an analysis that is used to identify the significance of protein 
expression by using EDM. The intensity of labelled peaks were then transfered to 
Biomarker Pattern Software in multivariate analysis to correctly classify the protein 
peaks and generate regression tree models. This model will identify potential biomarker 
candidates depending on the percentage of cases based on the intensity of the peaks. 
The alterations of protein expressions were first monitored in normotensive rats and 
SHR, followed by observations after the administration of extracts.  
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4.6.1 Univariate analysis 
Using EDM analysis, significant differentially expressed proteins (p < 0.05) 
were identified in protein peaks ranging from 2,500 to 40,000 Da. In the comparison 
between normotensive rats and SHR, all significant peaks from SHR  showed down 
regulation as compared to normotensive rats (expression dynamic range 1.8 to 32). In 
SELDI analysis, the relative expression of proteins are represented in the form of 
intensity.  
The down-regulated expression of protein peaks with m/z 3493.2, 22874 and 
33086 were two times lower. Other peaks were two times higher than respective peak in 
normotensive rat (NR) with m/z 2317.6 showing the highest down-regulation with 
32.34 fold change.  
After the administration of SF extract, seven protein peaks were found to be 
significantly altered. Those peaks were the ones with m/z 3493.2, 8303.3, 9445.0, 
16531.0, 18986, 22044 and 33086 as shown in Figures 4.16-4.22. However, these 
alterations did not show any extreme normalizing effetcs. Only peaks with m/z  8303.3 
and 9445.0 were slightly up-regulated after 10 days of treatment.  
In the case of BL extract only three peaks were found to be significantly altered 
after the treatment. The altered proteins were those with  m/z 2317.6, 4180.6 and 
8303.3. All these proteins were found to be significantly increased as compared to SHR. 
Typical spectra are shown in Figures 4.23-4.25. 
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Table 4.7: SELDI-TOF analysis demonstating the differences in protein profile 
of sera from normotensive and SHR rats. 
 
 
Data shows the down-regulation of protein peaks belongs to the non-treated SHR as 
compared to the same protein peaks belongs to normotensive rats.  p-value was 
obtained from the EDM.
m/z 
Peak Intensity 
Fold Changes p-value 
Normotensive (NR) SHR 
3 003.4 10.25 3.3 3.11 0.039 
11 029.0 21.58 7.08 3.61 0.039 
22 044.0 59.47 25.32 2.35 << 0.01 
33 086.0 49.72 25.35 1.96 < 0.01 
4 180.6 26.83 11.67 2.30 0.014 
13 230.0 43.99 14.01 3.14 0.028 
8 303.3 37.62 8.27 4.55 << 0.01 
2 317.6 25.64 0.79 32.34 0.014 
9 445.0 9.36 2.99 3.13 <<0.01 
3 493.2 94.32 47.76 1.97 0.014 
16 531.0 60.87 22.52 2.70 0.014 
1 617.5 30.31 4.13 7.35 0.028 
1 705.7 67.15 25.27 2.66 0.039 
1 794.3 45.27 16.79 2.70 0.028 
22 874.0 6.55 3.59 1.82 0.028 
18 986.0 2.63 1.27 2.06 0.014 
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Modification of  individual protein by administration SF extract 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4.16: Changes of serum protein profiles (m/z 3493.2) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 3493.2 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average. 
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Figure 4.17: Changes of serum protein profiles (m/z 8303.3) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 8303.3 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average. 
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Figure 4.18: Changes of serum protein profiles (m/z 9445.0) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 9445.0 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.19: Changes of serum protein profiles (m/z 16,531.0) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 16,531.0 in 
three different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.20: Changes of serum protein profiles (m/z 18,986) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 18,986 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.21: Changes of serum protein profiles (m/z 22,044) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 22,044 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.22: Changes of serum protein profiles (m/z 33,086) upon administration 
of SF F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 33,086 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Modification of  individual protein by administration of BL extract 
 
 
 
 
 
Figure 4.23: Changes of serum protein profiles (m/z 2317.6) upon administration 
of BL F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 2317.6 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.24: Changes of serum protein profiles (m/z 4180.6) upon administration 
of BL F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 4180.6 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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Figure 4.25: Changes of serum protein profiles (m/z 8303.3) upon administration 
of BL F. deltoidea. (A) Signal spectra of relative peak intensities at m/z 8303.3 in three 
different groups. Relative peak were exposed as mean, averaged m/z and intensity 
(n=4). (B) Histogram illustrating peak intensity average.  
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4.6.2 Multivariate analysis 
4.6.2.1 Comparison of healthy rat (normotensive rat) versus diseased rats 
(nontreated SHR) 
 Comparison of treated and nontreated SHR in multivariate analysis using 
Biomarker Protein Software (Ciphergen) to generate classification and regression tree 
(CART) model were shown in Figures 4.26-4.28. CART model 1 was generated from 
67 spectra. Interestingly, the model generated from BPS produced only one decision 
node based on a protein with m/z 4180.6 (2.30-fold down-regulated in the univariate 
analysis [Table 4.17]).  In cross-validation, a sensitivity and specificity of 16.6% and 
37.5% in identifying normotensive rats (NR/SD) against SHR were observed in this 
CART model (Figure 4.26).  
 
Figure 4.26: CART model 1: Normotensive rats (NR) versus nontreated SHRs.  
SD – normotensive rats, SHR – nontreated SHR. Figure was directly extracted from the 
software. 
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4.6.2.1 Comparison of healthy rat (normotensive rat) versus diseased rats 
(nontreated SHR) and treated rats (SHR-SF) 
 Comparison of NR, SHR and SHR-BL generated CART model using 67 spectra 
derived on CM-10. This model has two nodes with m/z of 33086 and 25076 (Figure 
4.27). However, from these results, no decision node could be produced. Therefore, no 
specifity and sensitivity values were obtained.  
 
Figure 4.27: CART model: comparison of normotensive rats, nontreated SHRs 
and SHRs treated with SF. 
 SD – normotensive rats; SHR – nontreated SHRs; SHR-F – SHRs treated with SF. 
Figure was directly extracted from the software. 
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4.6.3.3  Potential biomarker following administration of BL extracts  
 
 Similarly, 67 spectra from CM-10 arrays of NR, SHR and SHR-BL were used to 
generate another CART model. Two nodes were produced; m/z 1617.5 and 5059.7. 
However, from these results, no decision node could be produced. Therefore, no 
specifity and sensitivity values were obtained. This model achieves the correct 
classification of NR, SHR and SHR-BL with 16.7%, 25% and 25% respectively. 
 
Figure 4.28: CART model: comparison of normotensive rat, nontreated SHR and 
SHR treated with BL. 
 SD – normotensive rats; SHR – nontreated SHRs; SHR-B – SHRs treated with BL. 
Figure was directly extracted from the software. 
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 5.0 Discussion 
5.1 ACE activity inhibition  
ACE inhibitors are the first-line drug recommended in antihypertensive therapy 
(Joint National Committee, 1988). Thus, the ACE activity inhibitory assay was used as 
the preliminary assay in monitoring and evaluating the effect of SF and BL as 
antihypertensive agents. The potential of SF and BL aqueous extracts from F. deltoidea 
ACE activity inhibitory were assayed in vitro. This assay represents the in vivo activity 
of ACE, whereby HHL was used as a synthetic substrate in place of Angiotensin I (Ang 
I). If not inhibited, ACE will convert Ang I to Angiotensin II (Ang II) which is 
translated by this assay as the hydrolysis of HHL to form hippurate. Hippurate is a 
detectable compound and thus, could be measured spectrophotometrically (Cushman & 
Cheung, 1971). Ang II is a vasoconstrictor that promotes the constriction of the blood 
vessel and thus, leads to the increase in blood pressure. Therefore, inhibition of ACE 
activity could reduce the formation of Ang II and hence lowers the blood pressure.  
  The usage of HHL in ACE activity inhibitory evaluation is common in the 
determination of hypertensive properties of natural product extracts, for examples, the 
use of ripe strawberries in Brazil  (Pinto et al., 2008), Rabdosia coetsa – a plant used in 
Chinese folk medicine (Li et al., 2008) and cheeses (Sieber et al., 2010). In this study, 
addition of F. deltoidea extract(s) in the incubation exerted a significant reduction of 
hippurate. This could be explained as the reduction of HHL binding to ACE and thus, 
lowering the amount of hippurate produced. This indicated the inhibition of ACE 
activity; the higher the inhibition rate, the lower the amount of hippurate produced.  
  Results demonstrated that both extracts (SF and BL) produced the highest 
inhibition of ACE activity (75.3% and 78.4%) at a concentration of 0.4 mg/ml (Figures 
4.2 - 4.3). ACE inhibition by both extracts increased as the concentrations were 
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increased. The effectiveness of the extracts in inhibiting ACE activity was measured by 
the half maximal inhibitory concentration (IC50). In this study, SF and BL resulted in 
the following IC50 values; 0.13 mg/ml and 0.18 mg/ml respectively (Table 4.1). These 
results suggested that these extracts may contain active compound(s) that have potential 
in the inhibition of ACE activity, thus may help to reduce or control the development of 
hypertension.  
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5.2 In vivo anti-hypertensive study 
 Hypertension is a complex disease as it involves various mechanisms as its 
factor apart from ACE. In vivo study was performed with the aim to gather more 
knowledge and precisely understand the actual mechanism(s) of how SF and BL affect 
hypertension. Spontaneously Hypertensive Rat (SHR) is the animal model that is 
usually used to study essential or primary hypertension (Pinto et al., 1998). The 
hypertensive state for SHR begins at the age around 5-6 weeks and the systolic pressure 
will keep on increasing until it reaches 180 and 200 mmHg or higher in the adult phase 
(Conrad et al., 1995). In this study, SHR aged between eight to ten weeks were used for 
in vivo study as it was reported to be the most suitable experimental age (Canby et al., 
1989; Sanchez & Pettinger, 1981). The hypertensive condition of this model only 
allowed us to administer the extracts (SF and BL) in the form of drinking water at a 
dosage of 75 mg/kg supplied in ten days to minimize environmental stress during the 
treatment. The same protocol has been used in the study of the effect of potassium 
supplement in SHR (Jin et al., 1999) and the delivery method for melatonin to SHR in 
another drug discovery investigation (Nava et al., 2003). In order to validate the effect 
of SF and BL towards SHR, normal untreated Sprague Dawley (SD) rats were included 
in this study. The sera collected from all rats were then used in proteomics study to 
monitor the alteration of the protein profiles. Three different techniques were performed 
- SDS-PAGE, 2-DE and SELDI-TOF.    
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5.3 SDS-PAGE 
 Protein expression in SHR have been primarily studied using SDS-PAGE (Gros 
et al., 2000; Jin, et al., 1999). Electrophoresis, such as SDS-PAGE, is usually performed 
to monitor or observe  the expression of specific protein(s) in a biological sample before 
proceeding to another technique (Iwahashi et al., 2002).  In this study, SDS-PAGE 
analysis of rats’ serum revealed that the proteins were differentially expressed following 
the treatments as compared to non-treated SHR. The deregulated expression could be 
clearly seen in three different molecular weight (MW) regions; 6.9, 29 and 35.8 kDa 
(Figure 4.4). Protein expression in SF treated SHR (SHR-SF) and BL treated SHR 
(SHR-BL) serum (Figure 4.4) showed similar pattern with protein expression displayed 
by normotensive rats and also in Captopril treated SHR (SHR-Cp). All groups 
significantly showed distinguished pattern compared to nontreated SHR (diseased 
group). Comparing the serum protein profiles with the profile of normotensive rats; 
SHR-SF serum protein profile showed similar pattern in all three regions (Figures 4.5a-
c), which suggested a reversed/ normalised pattern of the SHR profile. However, SHR-
BL only showed the changes in MW regions 35.8 kDa and 29 kDa (Figures 4.5a-b). 
Thus, from this study it was hypothesized that both the extracts (SF and BL) may 
contain anti-hypertensive compound(s) or agent(s) that are affecting a few proteins in 
the serum protein in SHR.  
However, it is also important to note that SDS-PAGE may separate similar 
density proteins in one band. This usually indicates that the proteins are having the same 
MW or it could be isoforms of the same proteins. This limitation may reduce the 
sensitivity of protein identification due to two or more proteins being identified in one 
particular band as SDS-PAGE only separates the proteins based on its MW compared to 
2-DE;which separates proteins based on the MW and charges of the proteins. Therefore, 
a higher resolution technique, 2-DE was performed to overcome this limitation. 
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5.4   2-DE and Protein Identification using MALDI-TOF/TOF MS 
 The application of 2-DE as a tool to separate serum proteins resulted in highly 
reproducible gels inter sample and inter treatment groups (Figure 4.6). In the present 
study, analysis of 2-DE gel protein spots revealed that the expression levels of twelve 
protein spots that were significantly altered when the 2-DE serum protein profiles of 
normotensive rats were compared to the profiles of nontreated SHR rats. The spots were 
subsequently identified as plasma retinol binding protein, serum albumin fragment, 
clusterin, complement c3, haptoglobin, alpha 1 macroglobulin (2 spots), actin, alpha 1 
antiproteinase, alpha 2HS glycoprotein and Apolipoprotein H. With the exception of 
clusterin, α2HS glycoprotein and actin, all other proteins have been previously 
identified to be associated with hypertension. Their levels were also reported to be 
altered in SHR as well as in patients with hypertension. In this study, the expression of 
the seven proteins appeared to be altered when similar experiments were performed on 
the sera of SHR treated with SF and BL. These proteins were alpha 1 antiproteinase, 
haptoglobin, alpha 1 macroglobulin, apolipoprotein H, complement C3, serum albumin 
and plasma retinol binding protein. However, protein with the spot number 96 was not 
identified by MALDI-TOF/TOF due to low spot volume. 
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5.5  Serum proteins related to hypertension 
5.5.1 Alpha 1 antiproteinase (A1AT) 
Alpha 1 antiproteinase is also known as alpha 1 antitrypsin (A1AT). This protein 
belongs to a family of serine protease inhibitors (serpins) (Gettins, 2002). A1AT is an 
acute phase protein produced in response to inflammation and is produced by the liver 
to protect the immune system. A1AT down-regulates inflammation by inhibiting 
elastase, an enzyme produced by inflammatory cells which will freely break down the 
elastin in the pulmonary and lung systems (Kushner & Mackiewicz, 1993).  
Based on the results, this protein was up-regulated by three folds in SHR rat 
serum as compared to normotensive rat serum (Table 4.4 and Figure 4.13). However, 
the expression of A1AT in SHR was down-regulated following the treatments with SF 
and BL of F. deltoidea; a closer pattern to the expression of A1AT in normotensive rat 
serum (Figure 4.13).  
A1AT may be associated to hypertension as the elevation of inflammation-
sensitive plasma protein (ISPs) i.e. orosomucoid, fibrinogen, haptoglobin, ceruplasmin 
including A1AT has been observed in virtually all hypertensive incidences (Engström et 
al., 2002). The level of A1AT was observed to elevate as the human blood pressure 
increased (Engström et al., 2006). These studies help to strengthen the observed pattern 
revealed in this study. A1AT was also found to be elevated in increased incidence of 
cardiovascular diseases (Engström et al., 2002). Another study by Friedman (1990), 
reported that the widely accepted marker of inflammation, leukocytes, is associated in 
the development of hypertension. Based on these studies, it could be suggested that 
hypertension promotes inflammation (Chae et al., 2001). However, the significance of 
this association is still unclear due to the complex relationship between systemic 
inflammation, vascular cells activation and structural changes in the arteries. Therefore, 
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the link between these conditions needs to be explored (Pauletto & Rattazzi, 2006). 
Result from this study suggested that, SF and BL extracts may help in regulating 
inflammation or the causes of inflammation since the expression of this protein in SHR 
was down-regulated after the administration of the extracts. 
#FDR
   
 
5.5.2 Haptoglobin (HPT) 
Besides A1AT, haptoglobin (HPT) is another inflammation-sensitive protein 
found to be elevated in expression during the incidence of cardiovascular disease and 
cardiovascular risk. These incidences may be associated with cholesterol level which 
contributes to arteriosclerosis leading to damage of the arteries. HPT is highly 
synthesized by hepatocytes and is also found in adipose tissues (Chiellini et al., 2004; 
Hanley et al., 1983; Haugen et al., 1981). However, there are also evidences showing 
that it could be found in the skin, lungs, kidneys and heart (D'Arniento et al., 1997; 
Kalmovarin et al., 1991). HPT found in the arterial tissues is normally bound to free 
haemoglobin released by erythrocytes in blood system. Serum HPT may be involved in 
hypertension based on its nature as an anti-inflammatory protein released during acute-
phase condition. Any inflammation may increase the level of plasma HPT. However, 
the amount and role of liver-derived plasma HPT protein compared to artery-derived 
plasma HPT protein in arterial wall remains unclear (deKleijin et al., 2002). de Kleijin 
and his group reported the artery-derived plasma HPT involved in arterial restructuring 
as the serum HPT mRNA and protein expression were elevated after a sustained 
increase and decrease in blood flow. They have also suggested that the function of HPT  
 
Note: 
#FDR
 indicates proteins which were significant based on ANOVA but does not comply with FDR 
significance level. 
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in arterial restructuring is facilitated by cell migration confirmed that HPT was involved 
in artery restructuring as the expression of HPT was found to be elevated following  
balloon dilation during angioplasty (Smeets et al., 2003).   
From this study, HPT (spot 99) was down-regulated in normotensive rat serum 
compared to SHR rat (Table 4.4 and Figure 4.10). This suggested that the normal blood 
flow prevents damage of the arterial structure thus, require very minimal repair by HPT. 
As a result, less HPT will be present. SHR rats experience increase of blood flow, 
which then causes damage to the artery and thus increasing the demand for restructuring 
and anti-inflammatory activity. Expression of HPT increased following administration 
of the extracts (SF and BL). One possible explanation would be an arterial repairing 
action/mechanism triggered by the extracts. The presence of these extracts probably 
stimulates the expression of HPT, and thus promotes repair or restructuring of the 
artery, which then triggers dilation of the artery. Eventually this condition may promote 
lowering of blood pressure in the artery of SHR rats. 
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5.5.3 Alpha 1 macroglobulin (A1M)      
Alpha 1 or α1-macroglobulin (A1M) belongs to a family of large glycoproteins 
that inhibits all four types of proteinases by trapping mechanism (Sottrup-Jensen, 1989). 
Three commonly expressed α-macroglobulins in rats are α1-macroglobulin, α2-
macroglobulin and α1-inhibitor 3 monomer (Eggertsen et al., 1991; Warmegard & 
Johansson, 1992). In several rat tissues, α1-macroglobulin inhibit serine proteinases 
group namely tonin (Boucher & Genest, 1974). The amount of A1M correlates with the 
amount of tonin.  
Tonin activity is characterised by release of the vasoconstrictor peptide, Ang II 
directly from Angiotensinogen (AG) (Grise et al., 1981) or from other peptides 
presenting the sequence of the N-terminal of AG (Pesquero et al., 1982). Findings by 
Ikeda and Arakawa (Ikeda & Arakawa, 1984) demonstrated the capability of tonin to 
also release bradykinin – a potent vasodilator. Thus, tonin was proposed to be involved 
in the kinin-tensin system; a system that is able to generate both pressor (Ang II) and 
depressor (bradykinin) directly. The formation of tonin-A1M complex however, still 
allows the catalytic site to accept low molecular weight substrates but the bigger ones 
will be inhibited (Pesquero, et al., 1982). Taking into consideration that most substrates 
are small in size, the tonin-A1M complex is still able to generate Ang II from Ang I, 
even when Ang I converting enzyme (ACE) activity is being inhibited by the enzyme 
inhibitors. The complex (tonin-A1M) probably still retains esteroprotease activity of 
tonin, therefore direct production of kinin continues as opposed to the Ang II release. 
The complex therefore, may play an important role in the control of blood pressure or 
perfusion in the circulating blood, vascular or tissue surfaces (Ikeda et al., 1988). Result 
of this study demonstrated the importance of A1M as inhibitor for tonin reaction, which 
in turn help to regulate the release of Ang II and aldosterone secretion and kinin 
production, thus its expression was displayed in normotensive rat (Figure 4.11). 
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Hypertension in SHR rat probably occur as a result of Ang II accumulation via two 
directions; firstly the lack of A1M expression hence tonin activity is not inhibited 
relating to the increase of Ang II release and secondly the Ang II release by ACE 
activity. The uncontrolled release of Ang II promotes constriction of the blood vessels 
and finally increases the blood pressure. Treatment with the extracts (SF and BL) 
displayed their effect towards the up-regulation of A1M expression levels (spots 
108
#FDR
 and 117) (Figure 4.11), and subsequently may help to lower the blood pressure 
in SHR rats receiving SF and BL treatments.  
 
5.5.4  Apoliporotein H (APOH) 
Apolipoprotein H is formerly known as β2-Glycoprotein I (β2GI). In previous 
studies, β2GI has been identified as a component of circulating plasma protein and 
characterized as a lipoprotein, thus it was named as Apolipoprotein H (APOH). This 
lipoprotein is a unique lipoprotein as the APOH characteristic differ from other flexible 
lipoproteins (Lee et al., 1983). APOH is synthesized in the liver and distributed freely in 
serum (Polz & Kostner, 1979).  
The precise function(s) of APOH are yet to be determined. APOH binds to 
negatively charged substances such as heparin, phospholipids and dextran sulfate.  
APOH is involved in anti-coagulation activity in serum by preventing the activation of 
the intrinstic blood coagulation cascade whereby it will bind to phospholipids on the 
damaged cells surface. APOH appears to inhibit the release of serotonin by the platelets  
 
Note: 
#FDR
 indicates proteins which were significant based on ANOVA but does not comply with FDR 
significance level. 
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thus preventing the activation of the ADP-induced aggregation. It’s binding to the 
agglutinating and negatively charged compounds causes the inhibition of agglutination 
by contact activation of the intrinsic blood coagulation pathway (Schousboe, 1985). 
In normal blood clotting process, blood coagulation occurs in damaged blood 
vessels to prevent loss of blood. However, the formation of blood clots due to the 
formation of thrombin may block the flow of blood and oxygen through the blood 
vessel. Small blood clots that break off may get stuck in the tiny capillaries and totally 
block the blood flow. Blood pressure will increase due to these phenomena. APOH 
causes a reduction of prothrombinase binding sites on platelets and reduces the 
activation caused by collagen when thrombin is present at physiological serum 
concentrations of APOH suggesting a regulatory role for APOH in coagulation (Nimpf 
et al., 1986). 
 APOH is also considered as a clinical marker for cardiovascular risk as the 
concentration of APOH is associated to metabolic syndrome alterations and vascular 
diseases in type 2 diabetes. Besides, APOH also involved in activation of lipoprotein 
lipase in lipid metabolism (Nakaya et al., 1980). 
  In this study, the level of APOH expression in SHR was down-regulated 
compared to the normotensive rat (Table 4.4 and Figure 4.13). This indicated that 
reduction of APOH in SHR may cause the agglutination and coagulation of blood 
therefore, increasing the pressure of blood flow. The expression dynamic result (spot 
259) suggested the normalising effect of both extracts towards APOH as the expression 
was up-regulated compared to the SHR and eventually follow the normotensive rat’s 
expression pattern (Figure 4.13). Therefore, it could be suggested that the 
administration of SF and BL extracts may contribute to the lowering of blood pressure 
by controlling the coagulation activity in blood. 
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5.5.5 Complement C3 precursor (CO3) 
Complement C3 (CO3) is a protein that will be cleaved to produce two chains 
(alpha chain [CO3a] anaphylatoxin and beta chain [CO3b]) following removal of four 
Arginine residues by CO3 convertase (Nakagawa & Komorita, 1993). 
 CO3 mainly involved in the activation of complement system in both classical 
and alternative complement pathways. Activated CO3b will bind to cell surface 
carbohydrates and also involve in immune aggregation. CO3a anaphylatoxin is a 
mediator of local inflammatory process by enhancing contraction of the smooth 
muscles, increases vascular permeability and causes histamine release from mast cells 
and basophilic leukocytes (Nakagawa & Komorita, 1993). These mechanisms cause 
phagocytosis of opsonised particles, activate later stages of complement (from 
formation of CO5 convertase) and induce inflammation. 
Elevation of CO3 was found in diabetes cases related to insulin resistance 
(Muscari et al., 2007; Ylitalo et al., 2001). Most of them hypothesised that the elevation 
of CO3 may be induced by inflammation caused by deposition of lipid in the plasma. 
However, none of the researchers confirmed this mechanism. 
Nevertheless, the role of CO3 or complement in hypertensive have also been 
studied in kidney of SHRs given deoxycorticosterone acetate (DOCA) and salt (Takagi 
et al., 1990). Since CO3 plays a role in IgA nephropathy, CO3 was found to be 
necessary for renal injury in DOCA-salt mice (Takagi, et al., 1990) as the kidney injury 
of CO5-deficient mice administrated with DOCA and was not as severe as wild-type 
mice treated with DOCA and salt (Raij et al., 1989). In renovascular hypertensive rats, 
CO3 shows its association in the left ventricular perivascular inflammation (Nicoletti et 
al., 1996) and also stimulated the pulmonary vascular constriction in rats (Morganroth 
et al., 1990). However, among these studies, only Zhi-Hong Lin and partners (2004) 
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reported the involvement of CO3 in arterial smooth muscle cell growth in hypertensive 
disease. 
Folkow (1987) and Sen et. al. (1974) reported that SHR showed exaggerated 
growth of cardiovascular organ in comparison with normotensive rats. Enhanced DNA 
synthesis and organ hypertrophy was observed in SHR rats before the elevation of blood 
pressure (Walter & Hamet, 1989). In cell culture studies, SHR-derived vascular smooth 
muscle cells (VSMCs) indicated exaggerated growth compared to cells from 
normotensive rats (Fukuda, Hu, et al., 1999; W. Y. Hu et al., 2002) and production of 
Ang II in homogenous cell was shown in the SHR derived VSMCs (Fukuda, et al., 
1999; Fukuda, Satoh, et al., 1999). Hu and team (2000) suggested the generation of the 
Ang II in VSMCs from SHR may due to the contractile changes to the synthetic 
phenotype in VSMCs from normotensive rats. Lin and partners hypothesized the 
exaggerated growth and synthetic phenotype of VSMCs is caused by genetic 
abnormalities. From their study, they have found that mRNA encoding CO3 is 
expressed only in VSMCs from SHR. This may explain the significant elevation of CO3 
(spot 85) in SHRs compared to normotensive rats observed in this study. CO3 was 
highly expressed in SHR compared to the normotensive rat with fold changes 3.52 
(Table 4.4). Similar pattern was observed in SHR-SF (Figure 4.9). However, the 
expression of CO3 in SHR treated with BL exhibited different pattern as compared to 
nontreated SHR (Figure 4.9). Thus, it could be suggested that CO3 may act as a 
potential target in SF treatment due to the decrease of CO3 expression after the 
treatment. However, treatment with BL did not affect the expression of CO3. The 
association of complement system with hypertension still remains a question even after 
Lin and partners found the association CO3 in arterial smooth muscle cells in SHR.  
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5.5.6  Serum albumin 
 Serum albumin levels have been previously associated with hypertension. In an 
epidemiological investigation, increasing albumin concentration in the serum within the 
physiological range was found to correlate with increase in systolic and diastolic blood 
pressure in men and women in all age groups (Høstmark et al., 2005). In this study 
results showed that the albumin spot was reduced significantly in normotensive rats and 
SHR-SF. This data is analogous to the epidemiology study by Høstmark and colleagues 
in which serum albumin in SHR is higher compared to the serum albumin in 
normotensive rats. However, the serum albumin appeared to be a 19.9 kDa fragment of 
the serum protein (68.7 kDa) (Figure 4.12). This fragment may be the results of the 
proteolysis of serum albumin although currently no information is available on the 
association of serum albumin with hypertension in rats.   
 
5.5.7  Plasma Retinol Binding protein (RETBP) 
 Plasma retinol binding protein (RETBP) was known as a protein for delivery of 
retinol to tissues (Quadro et al., 1999). Recently, endrocinology and metabolism study 
showed that RETBP could be associated with variables related to insulin resistance and 
diabetic complications (Takebayashi et al., 2007). However, none of the studies 
reported on the direct association of serum RETBP with hypertension. Buzio et al. 
(1994) reported that there was no difference in the level of RETBP in serum of patient 
given protein diet. Another study reported that RETBP level was elevated in pregnancy-
induced hypertension (Inoue et al., 2009). However, in the evaluation of the relationship 
between RETBP and essential hypertension in women, Solini et al. (2009) reported that 
RETBP level increased in naïve hypertension women and this correlates with the degree 
of intima-media thickness. Other study reported that the increased level of RETBP is 
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associated with subclinical inflammation in childhood obesity, inflammatory markers 
and other variables related to atherosclerosis. These findings imply that RETBP could 
be involved in the development of atherosclerosis which could also relate to 
hypertension. Our study showed a contrasting effect towards RETBP whereby the 
expressions in SHR were down-regulated as compared to normotensive rats, SHR-SF 
and SHR-BL (Figure 4.15). This difference could be explained by the fact that RETBP 
found in this study could have undergone some modifications. The protein was found to 
be present in the region of pI=6.51 instead of the actual pI= 4.69. 
From this study, it can be hypothesized that the extracts may have the capability 
to act as anti-hypertensive agent based on the similar trend of RETBP expression with 
normotensive rats.  
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5.6  SELDI-TOF analysis and data interpretation 
In the present study, F. deltoidea extracts (SF and BL) demonstrated a revealing 
antihypertensive effect based on in vitro ACE activity inhibitory study and 2-DE – 
MALDI-TOF/TOF analysis from in vivo samples. Realising the positive potential of 
these extracts, the serum protein profiles of all rats in all tested groups were further 
explored using SELDI-TOF. This technique was applied as it is a proteomic tool that 
enables the measurement of various sizes and characteristic of proteins in a blood 
sample especially for the low MW protein which could not be detected in 2-DE.  
Preliminary SELDI-TOF analysis was performed in order to observe the profiles 
of low MW serum proteins present in SHRs and normotensive rats. Differences between 
these profiles enable the determination of deregulated serum proteins. Characterisation 
was done by looking at the signal peaks which will give their exact mass per charge 
ratio (m/z). Only mass values within the range of 2,500 and 40,000 Da were considered 
in the analysis. Values less than 2,500 Da were excluded as it represents the signal noise 
from the matrix, buffers and reagents. All data were generated using Ciphergen Express 
Data Manager and univariate analysis of the protein expression was performed using 
Expression Dynamic Mapping (EDM) application. A total of 16 peaks were found to be 
significantly altered in hypertensive state. All the proteins showed down regulation in 
the sera from SHR rats as compared to the sera from normotensive rats (Table 4.7). 
The second part of analysis was aimed at identifying protein peaks which were 
affected by the administration of SF and BL extracts. The analysis was done by directly 
comparing the profiles of SHR, normotensive and treated SHR. Following treatment 
with BL, three protein peaks with the m/z 2317.6, 4180.6 and 8303.3 demonstrated 
5.02, 1.50 and 1.43 folds changes in their expression (Figures 4.23 - 4.25). These 
proteins showed a normalisation effect as the expression of the affected protein 
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increased after the administration BL. The administration of SF affected more protein 
peaks (seven peaks), however, the level of alteration was somewhat minimal and less 
significant. The difference in fold change was only 1.38, 1.27 and 1.15 as shown by 
peaks with m/z 9445.0, 8303.3 and 16,531 (Figures 4.16 – 4.22). 
 Even though SELDI-TOF analysis allows researcher to confidently distinguish 
protein profiles of several subject groups, the identities of these proteins are not 
determined. Further characterisation and identification will require another technique. 
Nonetheless, the information in the form of protein mass (m/z) could be further used to 
investigate potential disease biomarker. In SELDI-TOF multivariate analysis, potential 
biomarker candidates were investigated using Biomarker Pattern Software™ (BPS). 
This software potentially allows researchers to establish a decision tree that could 
correctly classify the samples group/origin. Statistically significant peaks obtained from 
EDM univariate analysis will be used to generate the Class and Regression Tree 
(CART) model. This software will analyse all data step wise by looking at the intensity 
ratio and the frequency of a specific peak that is present in different groups.  
Comparison between SHR and normotensive (NR) data analysed by BPS 
exhibited only one potential biomarker candidate in these groups which is the peak with 
m/z 4,180.6 (Figure 4.26). Based on collated data, the software automatically set the cut 
off intensity level of m/z 4,180.6 at 13.667 whereby serum samples with the intensity > 
13.667 indicated NR subjects and those with the intensity ≤ 13.667 will be grouped as 
SHR subjects. Referring to Figure 4.26, CART model generated a small decision tree, 
with only a single node (Node 1) and two terminal nodes. Terminal Node 1 grouped all 
the serum with the intensity of m/z 4,180.6 ≤ 13.667. This terminal node classified 
100% of the serum sample as SHR and 0% as NR. Terminal Node 2 grouped all the 
serum with the intensity > 13.667, and hence 75% were classified as NR and 25% as 
SHR. In biomarker determination, a group with 100% subject differentiation is 
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considered absolute while the group that did not achieve 100% will be subjected to the 
next evaluation using other potential peak(s). The decision tree generated from this 
study suggested that 25% of SHR subject have been misdiagnosed as NR.  
Administration of SF to SHR generated a decision tree with three terminal nodes 
(Figure 4.27). Two peaks were chosen as potential biomarker candidates; m/z 33,086 
and 25,706. Node 2 classified the groups as NR or SHR/treated SHR based on m/z 33 
086 at the intensity cut off of 32.205. A total of 83.3% was correctly classified as NR in 
Terminal Node 3 (33,086 > 32.205). Node 2 were further analysed using m/z 25 706 at 
the intensity cut off of 0.641 to further distinguished SHR and treated SHR. In Terminal 
Node 1 (25,706 ≤ 0.641), none of the NR was misdiagnosed as SHR and 85.7% was 
classified as treated SHR. Terminal Node 2 (25,706 > 0.641) classified 75% as SHR. 
Based on this CART model, it could be suggested that these two m/z peaks were 
potential biomarker candidates. However, the use of these candidates could not produce 
an absolute classification and resulted with several misdiagnosed cases. 
On the other hand, administration of BL generated a decision tree with three 
terminal nodes but two different peaks were chosen as potential biomarkers; m/z 1617.5 
and 5059.7 (Figure 4.28). Node 2 classified the groups as NR or SHR/treated SHR 
based on m/z 1617.5 at the intensity cut off of 7.865. Only 71.4% was correctly 
classified as NR in Terminal Node 3 (1617.5 > 7.865). Node 2 was then further 
analysed using m/z 5059.7 at the intensity cut off of 11.067 to distinguished SHR and 
treated SHR. SHR comprised 85.7% of the group classified as SHR in Terminal Node 1 
(5059.7 ≤ 11.067) and 75% classified as treated SHR in Terminal Node 2 (5059.7 > 
11.067). Similarly as in the SF treatment, the two protein peaks were suggested as 
potential biomarker candidates could not produce an absolute classification and resulted 
with several misdiagnosed cases.  
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In this study, generation of this model serve as a trial method to identify 
potential biomarker candidates in research involving more than two groups of subjects 
(i.e. normal, diseased and diseased-treated). The decision trees produced were not 
absolute and could not uniquely distinguish the subjects. This could be due to the small 
size number used in the experiment. Increasing the sample size could lower the 
deviation between peak m/z values as well as intensities and in turn will improve the 
decision tree model. 
As a whole, treatment of SHR with SF and BL extracts demonstrated alteration 
of some low MW proteins expressions. These alterations leads to the identification of 
several potential biomarkers, alas these proteins could not highly distinguish each group 
as modelled by CART decision tree.   
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5.7  General Discussion 
Four different techniques were used to study the potential of F. deltoidea 
extracts with anti-hypertensive properties; ACE assay, SDS-PAGE, 2-DE and SELDI-
TOF-MS. The preliminary study using ACE inhibitory assay was conducted to monitor 
the ability of these extracts in inhibits ACE as a part of hypertension study. Initial 
observation of changes in protein profiles in the serum of treated SHRs (SHR-SF and 
BL) was performed using SDS-PAGE. To give better resolution, 2-DE was carried out. 
Differentially expressed proteins were identified by MALDI-TOF/TOF. Knowing the 
identities of these differentially expressed proteins will lead to an understanding on how 
they are involved in the anti-hypertensive effects of F. deltoidea extracts towards SHR. 
The limitation of 2-DE in observing low molecular weight proteins was overcome by 
the usage of SELDI-TOF. 
Results from the three approaches showed a degree of association with each 
other. In SDS-PAGE, treatment with BL resulted in minimum change in protein sera 
expression at MW region of 6.9 kDa (Figure 4.5c). This was also observed in 2-DE as 
treatment with BL mostly altered proteins expression in the middle MW region; range 
21-101 kDa (Figure 4.7). Specifically, the expression of ALBU and RETBP in SHR-BL 
exhibited similar expression as in non-treated SHR (Figure 4.12 and 4.15). A lesser 
number of significant peaks were altered in SHR-BL compared to SHR-SF in SELDI-
TOF – EDM application.  
It was apparent that some SELDI-TOF results may be similar to MALDI-
TOF/TOF results. The m/z of native protein peaks found in SELDI-TOF could be 
associated with the theoretical MW of proteins obtained from the SWISS-PROT 
database for proteins identified in MALDI-TOF/TOF analysis. Peaks at m/z 22,044 and 
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33,086 found in SHR-SF protein profile could be RETBP (MW: 23,220 Da) and APOH 
(MW: 33,197 Da) respectively.  
This study had revealed the anti-hypertensive potential of F. deltoidea extracts 
(SF and BL). Even though the direct mechanism on how these extracts affects 
hypertension remains unclear, this study has shown the effect of SF and BL of F. 
deltoidea extracts on several mechanisms - (1) ACE inhibition, (2) inflammation, (3) 
vasodilation and (4) anti-coagulation. 
 Based on the ACE activity inhibitory assay, it could be postulated that both 
extracts affect the hypertension primarily via ACE pathway. F. deltoidea may contain a 
certain compound(s) that mimic the characteristics of ACE substrate, thus, their binding 
will block enzyme activity. Another possibility would be allosteric binding of the 
compound to the enzyme, causing changes the in enzyme conformation and hence 
reduce the affinity of the substrate for the enzyme active site.  
Administration of F. deltoidea extracts to SHR rats caused alterations in sera 
protein profile. Based on the profile, it could be hypothesized that F. deltoidea may be 
acting as an anti-hypertensive through regulation of the kinin-tensin system via 
alteration of A1M expression. This will reduce the production of vasoconstrictors and 
promote the release of vasodilators thus lowering or regulating blood pressure. This 
observation correlates well with the observed results in ACE in vitro assay. Besides the 
kinin-tensin system, F. deltoidea extracts also showed noticeable effects towards 
inflammatory proteins (A1AT and HAPT) thus potentially may prevent arterial damage. 
F. deltoidea extracts may also posses anti-coagulation activity (through up-regulation of 
APOH) that reduces pressure in blood flow by minimizing the blockage of the vascular 
system. It has to be noted that these postulations are made based on the known function 
of the differentially expressed protein. Besides these three mechanisms, F. deltoidea 
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also affects the complement system (CO3) involved in inflammation pathway. 
However, the exact relation with hypertension could not be clearly postulated at this 
point. 
Even though this primary investigation on the effects of F. deltoidea towards 
hypertension gave informative clues, the actual mechanism of action could not yet be 
conclusively determined. While the mechanism of action remains unresolved, 
identification of potential biomarkers could complement this investigation. This study 
managed to identify several low MW proteins that could be used as potential 
biomarkers for hypertension. Further characterisation of these proteins will provide 
insights regarding on the actual mechanism(s) involved.   
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6.0  Conclusion 
 
 In summary, F. deltoidea aqueous extracts (SF and BL) exhibited potential as anti-
hypertensive property. It can be concluded that; 
 F. deltoidea extracts showed an inhibitory activity towards ACE in vitro. 
 F. deltoidea extracts may act as anti-hypertensive agents via alterations of sera 
protein profiles of SHR rats as observed in 2-DE after the administration of aqueous 
extracts. 
 F. deltoidea extracts had also altered low MW proteins (LMWP) in SHR. SF altered 
proteins expressions at m/z 3493.2, 8303.3, 9445, 16 531, 18 986, 22 044 and 33 
086  Da and BL altered smaller proteins in expressions at m/z 2317, 4180.6 and 
8303.3 Da.  These LMWPs might be the potential biomarker candidates. 
As a while, SF may be more effective as anti-hypertensive agent when compared to 
BL. In SDS-PAGE, SF exhibited preliminary sera protein profiles changes in all MW 
regions. However, BL affected only two MW regions. The protein expression of SHR 
treated with SF showed normalizing effects as observed in 2-DE. BL did not resulted in 
normalizing effects towards CO3. Lastly, SF affects more LMWP compared to BL.  
In conclusion, administration of aqueous extracts of F. deltoidea showed anti-
hypertensive effects. However, the exact mechanisms involved remain unclear. The results 
however, do support traditional claims that F. deltoidea helps in improving blood 
circulation.  
 
